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ABSTRACT 
 
A NOVEL IN VITRO PDE7 INHIBITOR INHIBITS IL-2 GENE EXPRESSION IN 
ACTIVATED T CELLS AND INDUCES APOPTOSIS IN A B-CELL LINE AND 
MONOCYTIC CELL LINE  
 
Author: Chenjia Xu 
Advisor: Thomas C. Chiles, Ph.D. 
 
 Elevating intracellular cAMP levels can result in a wide range of anti-
inflammatory effects and growth arrest and apoptosis in cancer cells, marking 
phosphodiesterases (PDEs) as potential targets for inflammatory diseases and cancer 
treatment. PDE7A is proposed to be a new therapeutic target for its ubiquitous expression 
in proinflammatory and immune cells. A Barbituric acid based compound, BC12 was 
identified as an in vitro PDE7 inhibitor in fission-yeast-based high-throughput screen. 
Analysis of this compound on the activation of Jurkat T lymphocytes, mouse and human 
primary T cells reveals inhibition of IL-2 production, though cell viability is not 
significantly impacted. Real-time RT-PCR and mRNA stability assays indicate that the 
inhibition of IL-2 production by BC12 is attributable to transcriptional repression without 
accelerating IL-2 mRNA decay. By contrast, compounds of similar structure with that of 
BC12 exhibit varying effects on IL-2 production that does not correlate with their in vitro 
PDE7 inhibitory activity, suggesting that the in vivo target of BC12 responsible for these 
effects may not be PDE7. Our study further reveals that BC12 inhibits IL-2 transcription 
through targeting NFAT and NFκB-mediated pathways. Preliminary investigation on 
other T helper cell cytokine secretion indicates that BC12 has a potential to selectively 
inhibit Th2 cytokines. Our data suggest that BC12 may present a novel anti-inflammatory 
drug for its immunosuppressive and potential immunomodulatory effects. Analysis of 
BC12 on a human B-cell line and a monocytic cell line demonstrate its pro-apoptotic 
effects in a dose-dependent manner. Titration of BC12 on human diffuse large B-cell 
lymphoma (DLBCL), LY18 cells, and human primary B cells reveals that BC12 induces 
cell death more effectively in DLBCL LY18 cells than normal B cells, suggesting the 
anti-cancer potential of this compound. 
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INTRODUCTION 
 
I.  Cyclic Nucleotide Phosphodiesterases and Their Roles in Immune System 
A.  cAMP Signaling in Immune System  
 Adenosine 3', 5'-cyclic monophosphate (cAMP) is a ubiquitous second messenger 
that plays a central role in signal transduction and regulation of cellular responses. It is 
generated by adenylyl cyclase (AC) and hydrolyzed by phosphodiesterase (PDE) [1, 2]. 
The intracellular level of cAMP is precisely controlled and organized spatially and 
temporally. Adenylyl cyclases are activated through occupation of respective upstream G 
protein receptors by their ligands. There are at least ten isoforms of adenylyl cyclase and 
eleven families of phosphodiesterases in mammalian cells that allow tissue and 
differentiation specific regulation and compartmentalization of cAMP signaling [2].  
Protein kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) are 
the major effector enzymes of cAMP signaling [1]. Binding of cAMP to PKA releases 
catalytic domains of the kinase from regulatory domains. These catalytic domains are 
free to translocate and phosphorylate enzymes, transcription factors and ion channels, and 
therefore regulate a large scale of cellular response and gene expression [2]. Targeting 
cAMP pathway can be achieved through respective G-protein coupled receptors, adenylyl 
cyclases, phosphodiesterases, and downstream PKA activity.  However, increasing of 
adenylyl cyclase activity only results in transient change of cAMP level due to 
compensation of increased downstream PDE activity [3].      
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       Figure 1. cAMP signaling pathways in asthma therapy [2]. The figure is lifted from 
Pierre, S., Eschenhagen, T., Geisslinger, G., and Scholich, K. 2009. Nat Rev Drug Discov. 
8(4):321-35. 
 In the early 1970s, cAMP was reported as a general immunomodulator through an 
inhibitory action on immunologic and inflammatory functions [4]. Elevation of 
intracellular cAMP levels results in a wide range of anti-inflammatory effects, such as 
decreased pro-inflammatory cytokine generation, decreased proliferative response, and 
decreased surface marker expression in leukocytes [5]. Manipulating cAMP levels in 
immune cells has many clinical applications [6]. Several drugs for inflammatory diseases, 
such as asthma and chronic obstructive pulmonary disease (COPD), act through 
increasing cAMP levels  (Figure 1) [2, 6].  
 Additionally, the cAMP signaling pathway has also drawn increasing attention as 
a regulator of hematopoietic cell proliferation and apoptosis. It has been frequently 
reported that elevation of cAMP level arrests proliferation or induces apoptosis in 
malignant lymphoid cells [6–10]. However, the mechanism of cAMP-mediated apoptosis 
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pathogenic and immunogenic potential of the adeno-
virus backbone, two or more genomic regions are 
deleted in the newer generations of adenovirus vectors 
(‘double-deleted’ or ‘gutless’ adenovirus, respectively). 
Despite the use of these new generations of adenovirus 
vectors or cardiotropic subtypes of adeno-associated 
virus, in our opinion, the possibility of routine gene 
therapy is not a likely alternative to drug treatment in 
the near future.
AC activators in heart failure. Colforsin daropate 
hydrochloride, a direct AC activator with some selec-
tivity for AC5 compared with AC2 and AC3 (REF 85) 
but unknown affinity for AC6, shows potent inotropic 
and vasodilatory effects and is approved in Japan for 
the treatment of acute heart failure86. Given its action 
downstream of β-adrenoceptors, inotropic effects could 
be expected even in the presence of catecholamine 
refractoriness, but data in rabbits suggest that colforsin 
daropate hydrochloride loses its inotropic effect in 
animals treated chronically wi h isoprenaline, and even 
induces desensitization itself 87. Furthermore, to achieve 
the same stimulation of force in dogs as seen with dobu-
tamine or a PDE inhibitor, colforsin daropate hydro-
chloride exerted markedly more vasodilatation and 
tachycardia, a profile that is not well suited for th  tr at-
ment of heart failure88. The compound is not approved 
for the treatment of chronic heart failure and, given the 
detrimental effects of cAMP-increasing compounds in 
this condition, will probably never be.
Activation of ACs during asthma treatment
cAMP pathways in asthma. Asthma is a complex inflam-
matory disease that affects ~10% in the population in 
the Western world89. Classical anti-obstructive drugs 
for the treatment of asthma, such as β2-adrenergic recep-
tor agonists (that is, fenoterol or albuterol) or theophylline 
act through increased levels of cAMP (FIG. 2). Due to the 
necessity to increase cAMP levels to produce broncho-
dilatation and the fact that theophylline inhibits PDEs 
unselectively, inhibitors of cAMP-degrading PDEs are 
currently investigated for their use in asthma treatment90. 
PDE4 inhibitors specifically prevent the hydrolysis of 
cAMP in inflammatory cells and lung cells, thereby simul-
taneously decreasing the inflammatory response to the 
allergen and acting as a bronchodilator90,91. The second 
generation of PDE4 inhibitors, cilomilast and roflumi-
last, reached stage III clinical trials and showed beneficial 
effects in asthma and chronic obstructive pulmonary dis-
ease, although their effectiveness is limited by the need to 
use doses that can cause nausea and vomiting91. Human 
irway smooth muscle cells express several isoforms of 
adenylyl cyclases, including AC5, AC6 and AC9 (REF. 92), 
and direct activation of one of these isoforms could serve 
as alternative therapeutic approach to limit the adverse 
side effects reported with PDE inhibitors. Previous studies 
using the u selective AC activator forskolin could serve 
as proof-of-concept. For example, forskolin was shown 
to lower airway resistance after tracheal intubation95, 
fentanyl-induced bronchoconstriction96 and to induce 
bronchodilatation in patients with asthma97.
Figure 2 | cAMP signalling pathways in asthma therapy. Several bronchodilatator drugs act by increasing cyclic 
AMP (cAMP) levels. Treatment with β2-adrenergic receptor agonists (such as albuterol and fenoterol) stimulates cAMP 
generation by adenylyl cyclases (ACs) through the stimulatory G-protein GA
s
. Antagonists of the M2-muscarinic receptor 
(such as ipratropium bromide) can prevent the inhibitory G-protein (GA
i
)-mediated inhibition of ACs. Unselective 
phosphodiesterase (PDE) inhibitors (theophylline) and selective PDE4 inhibitors (such as cilomilast and roflumilast) 
increase intracellular cAMP levels by preventing the degradation of cAMP. Increased intracellular cAMP concentrations 
activate through protein kinase A (PKA) multiple target proteins including myosin light chain kinase (MLCK),  
Na+/K+-ATPase or Ca2+-activated K+ channels.
REVIEWS
328 | APRIL 2009 | VOLUME 8  www.nature.com/reviews/drugdisc
)''0DXZd`ccXeGlYc`j_\ijC`d`k\[%8cci`^_kji\j\im\[
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remains largely undiscovered. Although PKA is believed to be required in mediating 
apoptosis in most cases, the cAMP-mediated apoptosis in diffuse large B-cell lymphoma 
was reported to be associated with inhibition of the phosphatidylinositol 3-kinase 
(PI3K)/Akt pathway [10]. The expression level of the pro-apoptotic protein, Bim, from 
Bcl-2 family, is up-regulated in response to cAMP/PKA activation in lymphoid cells, 
which may be the link between PKA and caspase activation [8].     
 
B. PDE and Immune Cells  
 The multigenic family of cyclic nucleotide phosphodiesterase (PDE) hydrolyze 
the 3' ribose phosphate bond of cAMP or cGMP to their respective 5' -monophosphate 
and is the only way to degrade these cyclic nucleotides [1]. PDEs that hydrolyze cyclic 
pyrimidine monophosphates have also been discovered but have received little attention 
[11]. PDEs with homology greater than 65% in their catalytic cores are considered as the 
same family [1, 11]. There are at least 21 PDE genes expressed in mammalian cells that 
are divided into 11 families [1, 12]. Each gene produces one or more protein products due 
to splicing variation, yielding at least 80 different PDE proteins [1, 12]. Different PDE 
families share some structural similarity, including a conserved catalytic domain, and 
also own specificity in the respects of biochemical properties, substrate specificity, 
cellular localization, tissue-specific expression, and their sensitivity to pharmacological 
agents. PDE4, PDE7 and PDE8 are cAMP specific [1, 6]. Among the large PDE 
superfamily, PDE 3B, 4A, 4B, 4D and 7A1 are predominant in immune cells [5, 13].  
 Besides tissue-specific expression, PDE isoenzymes display remarkable specific 
cellular and subcellular localization. Subsequent compartmentalization of PDE activity in 
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cells makes it a potential target for specific pathways and disease processes [1]. Therefore, 
PDE inhibition is one of the major mechanisms applied to target cAMP signaling 
pathway for therapeutic purpose. The first PDE inhibitor, theophylline, was identified in 
1962 [14]. Since then, more selective and potent inhibitors for each PDE family have 
been synthesized and characterized. As a nonselective PDE inhibitor, theophylline has 
proven effective in controlling asthma through increasing cAMP levels (Figure 1) [1, 2].  
 Over the last two decades, there have been extensive efforts in developing PDE4 
inhibitors as therapeutic agents due to their anti-inflammatory properties. PDE4 is the 
major isoenzyme found in most T cell populations and PDE4 inhibitors have been shown 
to inhibit tumor necrosis factor (TNF) α production [15]. PDE4 specific inhibitors 
cilomilast and roflumilast reached stage III of clinical trials for treating asthma and 
COPD, but their usage is limited due to severe side effects of vomiting and nausea [1, 2, 
16, 17].  
 Recently, increasing attention has been drawn to the ability of PDE4 inhibitors to 
induce apoptosis in malignant lymphoid cells, which opens a new therapeutic area of 
cancer treatment [6–10]. Theophylline and PDE4 inhibitors were reported to augment 
glucocorticoid-mediated apoptotic effects in B cell chronic lymphocytic leukemia (B-
CLL) [9].  
 For the present, most of the PDE inhibitors are still used in biomedical and 
pharmaceutical research to study the functions of PDE isoenzymes [1]. The potential of 
PDE inhibitors as therapeutic agents is promising whereas their usage is still limited, 
calling for more specific PDE inhibitors for a better benefit-risk ratio [1]. 
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C. PDE7 Family: Expression and Function in Immune Cells  
 PDE7 is a cAMP-specific PDE family characterized as high affinity for cAMP 
(Km=0.2 µM) and low Vmax, but no sensitivity to PDE4 inhibitors such as rolipram [1]. It 
was first isolated at the gene level from a human glioblastoma cDNA library in 1993 
[18]. Since then, two genes have been identified in the PDE7 family, PDE7A and 
PDE7B, in mouse, rat and human [11, 18–21]. Although these two genes share structural 
similarity, they exhibit distinct distribution patterns [21, 22]. 
 PDE7A mRNA is highly expressed in human proinflammatory and immune cells, 
as well as in endothelial cells [22]. Three splice variants derived from the same gene have 
been identified. PDE7A1, the most well understood splice variant, is abundant in T 
lymphocytes, bronchial epithelial cells, airway and vascular smooth muscle cells, lung 
fibroblasts, and eosinophils. PDE7A2 has only been detected in cardiac myocytes at the 
protein level. PDE7A3 was found expressed in human CD4+ T cells after stimulation 
with anti-CD3/CD28 antibodies but not naive T cells [11, 22, 23]. PDE7A was also 
reported to be expressed in human B-lymphocytes and its expression is up-regulated by 
elevation of intracellular cAMP as a compensatory feedback mechanism [24]. The overall 
expression of PDE7A mirrors the distribution of PDE4, which leads to a reasonable 
speculation of its potential to be another anti-inflammatory target [22].  
 PDE7B was cloned and characterized using a bioinformatics approach in 2000. 
The deduced amino acid sequence of human PDE7B is 64% identical to that of PDE7A, 
with 67.1% identity in the catalytic domain and almost identical cAMP binding sites [19, 
20]. PDE7B mRNA is most abundantly expressed in the brain, heart, skeletal muscle and 
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pancreas, with little overlapping in distribution compared to PDE7A, indicating tissue-
specific functions of these two isoenzymes [19, 21, 24]. Three PDE7B splice variants 
were identified in rats, with PDE7B1 most widely distributed and PDE7B2 restricted to 
testis. PDE7B1 was proposed to play a role in neural activity and memory function [19–
21, 24]. It is notable that PDE7B mRNA is also detected in a low transcriptional level in 
T-lymphocytes [24]. 
 In addition to the ubiquitous expression of PDE7A in immune cells, accumulating 
evidence support that PDE7A plays a role in regulating inflammatory responses. Both 
PDE7A1 and 7A3 are up-regulated in T cells after stimulation [23, 25]. Li et al. reported 
that PDE7A antisense oligonucleotides inhibited cell proliferation and IL-2 production in 
both Hut78 T cell line and primary CD4+ T lymphocytes. The inhibition was associated 
with an increase in the cAMP level and could be reversed by a PKA antagonist [25]. 
However, PDE7A deficient mice were reported to have functional T cells, but 
unexpectedly exhibit a significantly enhanced antibody response, opposing the role of 
PDE7A in T cell activation but suggesting its potential role in B cell function [26].  
 Although PDE7B was considered not present at an appreciable level in immune 
cells, it was recently reported that B-CLL cells overexpressed PDE7B [7]. Both selective 
inhibition of PDE7 and dual inhibition of PDE4/7 kill CLL cells at concentrations that 
have little effects on normal B cells, suggesting PDE7B as a potential therapeutic target 
for CLL [7]. However, inhibitors that selectively and potently inhibit PDE7B are in need 
to confirm its role in CLL malignancy.  
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D. Fission-yeast-based High Throughput Screen for PDE Inhibitors   
 The discovery of selective inhibitors to PDE7 family has allowed more efficient 
assessment of its specific role in immune function and clinical potential. BRL50481, a 
pure competitive inhibitor discovered in 2004, is the only commercially available PDE7 
inhibitor to date [27]. It effectively inhibits PDE7A with IC50 of 200 nM, while 
moderately inhibits PDE7B [28]. BRL50481was found to act additively with PDE4 
inhibitors to suppress TNFα release from stimulated human monocytes [27].  Although 
PDE7 has shown a remarkable potential to serve as therapeutic targets, there are only a 
few selective PDE7 inhibitors that have been identified so far, and specific inhibitors to 
either isoenzyme or each splice variant are not available [28]. The identification and 
characterization of a selective PDE7A or 7B inhibitor or activator would facilitate the 
studies of PDE7A versus PDE7B functions, as well as generate more specific therapeutic 
agents. 
 Since most of the inhibitor development is based on structural characterization of 
active sites and novel synthesis, those newly developed inhibitors are not readily 
available to the research community. Our collaborator, Dr. Hoffman at Boston College, 
developed a novel fission yeast-based high throughput screen to identify new PDE 
inhibitors. The fission yeast Schizosaccharomyces pombe responses to extracellular 
glucose levels through a cAMP-signaling pathway. High glucose levels activate adenylyl 
cyclase through a G protein coupled receptor, generate a cAMP signal and lead to 
subsequent PKA activation. A fusion gene fbp1-ura4 is under a promoter repressed by 
PKA activity in response to cellular cAMP level. Yeast grown in a high glucose 
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environment require uracil to survive unless cAMP signaling is inhibited. Defects in 
glucose signaling pathway result in constitutive expression of fbp1-ura4 fusion gene, 
allowing yeast strains grow in high glucose environment lacking uracil, while conferring 
sensitivity to 5-fluoroorotic acid (5-FOA) [28].  
 Fission yeast strains with defects in glucose signaling were constructed with 
mammalian PDE genes as the only PDE activity. PDE inhibitors augment intracellular 
cAMP level and confer 5-FOA-resistant growth. Therefore, this platform can be used to 
screen for compounds with PDE inhibitory activity in a high-throughput fashion [28]. 
 
E. Identification, Structure and In-vitro Characterization of BC12 and Related 
Compounds  
 A series of novel compounds were identified as PDE7A or 7B inhibitors by the 
Hoffman lab based on their ability to stimulate 5-FOA-resistant growth in PDE7A or 
PDE7B recombinant fission yeast stains. In vitro PDE assays confirmed the PDE7 
inhibitory activity of these compounds. Among them, BC12 is one of the best PDE7A 
inhibitors in both high-throughput screening and in vitro assay. The IC50 on purified 
PDE7A catalytic domain is 1 µM, compared to 0.2 µM of BRL50481. Interestingly, 
BC12 acts as an activator on PDE7B catalytic domain with AC200= 0.1 µM. To further 
confirm, PDE7B from rat cell extracts was used as a substrate. BC12 acts as an inhibitor 
of full-length rat PDE7B with IC50 of 200 nM (Thomas Rich, personal communication). 
Based on the high throughput screening and in vitro PDE assay, BC12 is a potent in vitro 
PDE7A and 7B inhibitor. 
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                            Figure 2. The Molecular Structure of BC12 
 
 Structurally, BC12 is a barbituric based compound (Figure 2). Barbiturates are 
used for the treatment of intracranial hypertension, but the effect of neuroprotection is 
also associated with a loss of protective immunity. It has been reported that barbiturates 
exhibit immunosuppressive and immunomodulatory actions on lymphocyte and 
leukocyte function, including inhibition on T cell proliferation, differentiation, and 
cytokine production [29, 30]. 
 A series of analogs of BC12 were tested for their PDE inhibitory activity. Among 
7 derivative compounds, BC12-6 is the best PDE7 inhibitor and BC12-4 has no PDE7 
inhibitory effect when tested in the 5-FOA growth assay. 
 As a potent novel PDE7 inhibitor characterized in both fission-yeast growth assay 
and in vitro PDE assay, BC12 is a promising candidate for its potential 
immunomodulatory effects. My study will focus on the effects of BC12 and its derivative 
compounds on mammalian immune cells.  
 
II.  The Immune System  
 The immune system is the protective barrier of an organism and the defensive 
mechanism against invading pathogens.   
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 The immune system has two branches: innate immune system and adaptive 
immune system. The cells and molecules of both branches work as an integrated host 
defense system. Innate immunity serves as the first line of defense, which acts within 
minutes of infection and is followed later by early-induced responses. These responses 
can keep the infection under control in the early stages as well as influence the 
development of the adaptive immune response that will take several days. The innate 
immune system recognizes the common features of pathogens, and does not provide 
lasting protective immunity [31].   
 When the innate immune system fails to eliminate infectious organisms, an 
adaptive immune response is triggered, which is a stronger response with highly specific 
recognition of diverse foreign pathogens. The adaptive immune system comprises T 
lymphocytes, including CD8+ cytotoxic T lymphocytes and CD4+ T helper cells, and B 
lymphocytes, which mediate humoral responses. Both T and B lymphocytes develop 
through clonal expansion and differentiation into antigen-specific effector lymphocytes, 
and also generates memory lymphocytes that allow more rapid and efficient response 
upon re-infection [31].  
 
III.  T Lymphocytes   
A. The Development of T Lymphocytes  
 Like all other blood cells, T lymphocytes derive from self-renewing 
hematopoietic stem cells (HSC) in bone marrow. The fate determination of a pluripotent 
progenitor cell requires specific inductive signals and specified microenvironment. T cell 
progenitors migrate at a very early stage to thymus to develop into mature T cells [31]. 
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The developmental process in thymus can be distinguished by distinctive expression of 
cell-surface markers, and are divided into: double negative (DN) CD4-CD8- stage, double 
positive (DP) CD4+CD8+ stage and single positive (SP) CD4+ or CD8+ stage  (Figure 3) 
[32]. DN stage can be further broken down into four sub-stages based on the differential 
expression of surface protein CD44 and CD25 [33]. Immature DN thymocytes undergo 
receptor gene rearrangement that produces a diverse repertoire of T-cell receptors (TCRs) 
of individually unique antigen specificity. Rearrangement of two sets of receptor genes 
gives rise to two distinct T-cell lineages:  more than 95% α:β T cells and the rest 
γ:δ T cells [31]. After successful rearrangement of β-chain gene in α:β lineage cells, 
subsequently formed pre-T-cell receptor (preTCR) signals cells to proliferate, upregulate 
CD4 and CD8 expression, and initiate the rearrangement of the α-chain gene [31]. These 
developing cells go through positive selection by engagement of their TCR by self- 
major histocompatibility complex (MHC) molecules and negative selection by 
eliminating self-reactive cells [31]. T cells expressing receptors that recognize self MHC 
II are positively selected to the CD4+ lineage and those expressing receptors that 
recognize self MHC I are selected to the CD8+ lineage [32]. In the specific environment 
of the thymus, T cells are selected to generate a repertoire of self-MHC restricted and 
self-tolerant mature T cells. 
 Mature T cells leave the thymus and recirculate between the bloodstream and 
peripheral lymphoid tissues where they may encounter foreign antigens. They remain 
naive T cells until they encounter antigens in lymphoid tissues [31]. 
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Figure 3. The stages of T cell development [32]. The figure is lifted from E. Sebzda, S. 
Mariathasan, T. Ohteki, R. Jones, M. F. Bachmann, and P. S. Ohashi, Annual review of 
immunology, vol. 17, no. 3, pp. 829–874, 1999. 
 
B. Activation and Differentiation 
 Naive T cells are activated to proliferate and differentiate into effector T cells 
when they encounter their specific antigen presented in the form of peptide: MHC by 
antigen presenting cells (APC) in peripheral lymphoid tissues. Both ligation of TCR and 
costimulatory signals are required to trigger activation of naive T cells. Upon activation, 
T cells re-enter G1 phase of cell cycle and express an essential cytokine interleukin-2 (IL-
2) along with the α chain of IL-2 receptor (IL-2R). The α chain assembles with IL-2Rβ 
chain and common receptor γ chain to form a high-affinity IL-2 receptor, which binds to 
IL-2 to trigger the progression of cell cycle and following activation events [31]. 
 Naive CD8+ T cells are determined to become cytotoxic T lymphocytes (CTL), 
while naive CD4+ T cells can be induced by distinct cytokine cues from innate immune 
cells to different effector T-cell subsets, including Th1, Th2 and Th17 cells. Th1 cells, 
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which predominately produce IL-2, interferon (IFN) γ, and tumor-necrosis factor (TNF) 
β, are primarily responsible for initiating cell-mediated immunity [34]. Th2 cells produce 
IL-4, IL-5, IL-6 and IL-13, promote humoral immunity mediated by B lymphocytes, and 
stimulate the differentiation and activation of eosinophils [34]. Th17 cells are 
characterized by the production of pro-inflammatory cytokines IL-17A, IL-17F and IL-
22. They reside mainly at barrier surfaces and play an important role in autoimmunity 
[35]. The function of these effector cells is limited by another subset of T cells, 
regulatory T cells, including natural Treg cells (nTregs) and induced Treg cells (iTregs) 
[36]. nTreg cells develop in thymus during positive selection and suppress function of 
autoreactive T lymphocytes that have escaped negative selection. iTregs are generated in 
periphery after antigen-specific stimulation from naive CD4+ T cells [36]. Treg cells 
produce high level of inhibitory cytokines IL-10 and tumor growth factor (TGF) β and 
suppress effector T cell and dendritic cell function [37]. 
 The decision to differentiate into which effectors or regulatory cells is determined 
mainly by cytokines naive CD4+ T cells are exposed to during activation, and controlled 
by specific transcription factors.  IL-12, produced by dendritic cells and macrophages, 
and IFNγ produced by activated T cells are the principal cytokines to induce Th1 
development [36]. Activation of signal transducer and activator of transcription 4 (Stat4) 
by IL-12 and Stat1 by IFNγ leads to expression of the central transcription factor for Th1 
programming, T-bet [36]. IL-4 is the main cytokine that directs Th2 differentiation. Stat6, 
activated by IL-4, drives production of GATA-3, the central transcription factor for Th2 
programming [36]. The differentiation of Th1 and Th2 effector cells are self-reinforcing 
and counter-inhibiting [36]. Development of Th17 and extrathymic iTreg cells share the 
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requirement of TGF β, while differentiation into either Th17 or iTregs depends on the 
dominance of signaling by IL-6 or all-trans retinoic acid (at-RA) [38, 39]. Binding of at-
RA to the retinoic acid receptor (RAR) can potently inhibit Th17 development and 
promote Treg development [40–43], whereas signaling via IL-6 activates Stat3 and the 
lineage-determining transcription factor for Th17, an isoform of retinoic acid-related 
orphan receptor γ (RORγ), which is expressed in T cells (RORγt) [44].  
 
C. Signaling Events to T cell Activation: the TCR and CD28 Costimulatory Signals   
 T lymphocyte activation requires two signals, engagement of the TCR/CD3 
complex with antigen peptide/MHC molecule, and an additional signal from 
costimulatory molecules present on antigen-presenting cells (APC). The major 
costimulatory signal is provided by ligation of the T cell surface molecule CD28 with its 
ligands CD80/CD86 (B7-1/B7-2) [45]. Signaling from the TCR in the absence of 
costimulation renders a long lasting hyporesponsive state known as T cell anergy, which 
is important for peripheral tolerance.   
 The TCR/CD3 complex is comprised of the polymorphic α and β subunits (γ 
and δ  subunits in γ:δ lineage T cells) in association with the invariant TCR ζ chain, and 
γ, δ, and ε chains of CD3 molecule [46]. Signals from the TCR are transduced by ζ chain 
and all three CD3 chains, which contain the immunoreceptor tyrosine-based activation 
motif (ITAM) [46].  Phosphorylation of ITAM by membrane-bound Src family kinases 
Fyn and lymphocyte protein-tyrosine kinase (Lck) recruits additional protein tyrosine 
kinases (PTKs) to the TCR, such as z-chain associated protein kinase-70 (ZAP-70) [47]. 
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Figure 4. Signaling pathways activated by the TCR and CD28 molecules that lead to IL-2 
production in T helper cells [48]. The figure is lifted from S. L. Gaffen and K. D. Liu, 
Cytokine, vol. 28, no. 3, pp. 109–23, Nov. 2004.  
 
ZAP-70 phosphorylates a series of downstream adaptor proteins such as LAT, and also 
phospholipase Cγ 1 (PLCγ 1), which catalyzes the hydrolysis of phophatidylinositol 
lipids, generating inositol triphosphate (IP3) and diacylglycerol (DAG) [46]. IP3 induces 
intracellular calcium release, which in turn activates calcineurin, and together with DAG, 
activates protein kinase C (PKC). LAT recruits growth factor receptor-bound protein 2 
(Grb2) and guanine nucleotide exchange protein son of sevenless (Sos), which activates 
Ras/ extracellular-signal-regulated kinase (ERK) pathway (Figure 4) [47]. Calcineurin is 
upstream of nuclear factor of activated T-cells (NFAT), PKC can activate c-Jun N-
terminal kinase (JNK) and nuclear factor kappa B (NFκB) pathways, and ERK activates 
the transcription factor c-Fos. All these components regulate the expression of the IL-2 
gene [48]. 
control of message stability is a characteristic feature of
multiple cytokines including IL-6, GM-CSF and IL-3
[39]. The IL-2 message contains several AU-rich
elements (AREs) that target transcripts for rapid
degradation [40]. The half life of IL-2 mRNA is only
30e60 min, but this doubles in response to T cell
signaling. The IL-2 gene contains at least two cis
elements that regulate transcript stability, located in
both the 3# and 5# untranslated regions (UTRs) [41,42].
The stability element in the 5# UTR appears to be
a target of the JNK pathway, and both act in
a combinatorial manner to regulate message turnove .
2.3. Cells and tissues that express the gene
By far the majority of IL-2 is derived from activated
CD4C T cells. Flow cytometry studies analyzing IL-2
production by intracellular staining indicate that ap-
proximately 60% of activated CD4C T cells secrete IL-2
following non-specific stimulation (i.e., treatment with
phorbol 12-myristate 13 acetate (PMA) and a calcium
ionophore or antibodies that crosslink CD3 and CD28).
Whereas most or all T cells produce IL-2 immediately
following antigen stimulation, only the Th1 subset
produces it in large amounts after T elper cell
differentiation [43]. In addition, CD8C T cells also
secrete substantial quantities of IL-2 after stimulation of
their T cell receptors.
Minor amount of IL-2 are also produced by certain
antigen-presenting cells. For example, several B cell lines
have been shown to produce small amounts of this
cytokine [23,44]. More recently, dendritic cells (DCs)
were found to produce IL-2 transiently following
microbial challenge [45]. In these cases, IL-2 may serve
to enhance T cell activation, a hypothesis supported by
the finding that DCs derived from IL-2!/! mice are
impaired in the ability to promote T cell proliferation. In
contrast, however, macrophages apparently do not
produce IL-2 upon bacterial activation [46], so not all
modes of T cell activation require IL-2 from APC.
3. Protein
3.1. Descript on
The primary translation product of human IL-2
contains 153 amino acids, and is processed to a mature
form by cleavage of a 20 amino acid, hydrophobic
leader sequence. The N-terminal 20 amino acids are
essential for interaction with the IL-2 receptor, and an
IL-2 mimetic peptide has been developed that is
comprised of its N-terminal 30 amino acids (Fig. 5) [47].
From a structural standpoint, IL-2 is typical of
the short-chain Type I cytokines, despite a lack of
major sequence homology among these proteins [5,48].
PKC
CD4
PLCγ
NF-κB
Calcineurin
NF-AT
DAG
Ins(1,4,5)P3
PtdIns(4,5)P2
LAT
Ca2+
Lck
Raf
Ras
MEK
Vav
Rac cdc42
ERK
TCR
CD3CD3
ZAP70
LAT
Gads
SLP76
Grb2
Sos
AP-1
JNK
IKK
Fig. 4. Signaling pathways activated by the T cell receptor and CD28 molecules that lead to IL-2 production in T helper cells. After engaging MHC
Class II and antigen (not shown), the T cell receptor (TCR)/CD3 complex recruits CD4C and its associated kinase p56-Lck. Subsequently, the
cytoplasmic tails of various CD3 components become phosphorylated by p56-Lck, leading to recruitment of the kinase ZAP70, which proceeds to
phosphorylate various adaptors (e.g., LAT, SLP-76, Gads, and Vav) and also phospholipase C (PLC)g. LAT engages the Ras-Raf pathway, which
contributes to AP-1 formation. PLCg activity leads to production of diacylglycerol (DAG) and intracellular calcium (Ca2C), which in turn activates
protein kinase C (PKC) and calcineurin, respectively. PKC is upstream of both the JNK and NF-kB pathways, whereas calcineurin is upstream of
NFAT. Together, NFAT, AP-1, NF-kB and Oct-1 regulate the IL-2 proximal promoter (see Fig. 3). Figure kindly provided by Dr. Xin Lin,
University at Buffalo, State University of New York.
114 S.L. Gaffen, K.D. Liu / Cytokine 28 (2004) 109e123
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 CD28 signal is required in most cases for optimal IL-2 production and T cell 
activation, and for preventing the induction of anergy [49]. The function of CD28 can be 
partially attributed to augmentation of the TCR mediated signaling and therefore lower 
the TCR activation threshold, by facilitating the clustering of lipid rafts and formation of 
the immunological synapse (IS) [50]. However, the molecular basis of CD28 signaling is 
still largely controversy [50].  
 CD28 is a 44-kDa homo-dimeric protein expressed on the cell surface of resting 
and activated T cells [51]. The cytoplasmic domain of CD28 molecule lacks catalytic 
activity, and instead, it signals through binding to other signaling proteins via consensus 
motifs [51]. The phosphorylated YMNM motif in the cytoplasmic tail of CD28 can bind 
to adaptor protein Grb2 and the Src homology 2 (SH2) domain of PI3K [51]. In addition 
to Sos/Ras pathway, Grb2 can also recruit guanine nucleotide exchange factor Vav1, 
which activates Rho family protein such as Rac1, and subsequently JNK pathway [51]. 
PI3K catalyzes the production of phosphatidylinositol 3,4-phosphate (PIP2) and 
phosphatidylinositol 3,4,5-phosphate (PIP3), which associate with phosphoinositide-
dependent protein kinase 1 (PDK1) that in turn activates protein kinase B (PKB, or 
known as Akt). CD28 mediated PI3K/PKB pathway can provide survival signal to T cells 
by directly inhibiting apoptotic machinery [51], and control protein synthesis, cell 
metabolism and proliferation. 
 Downstream of YMNM motif, CD28 possesses two proline-rich motifs that can 
bind to additional signaling proteins, including PKCθ and an actin-binding scaffold 
protein Filamin A (FLNA) [51]. FLNA is reported to be important for the movement of 
PKCθ to the central supramolecular activation cluster (cSMAC) [51]. PKCθ provides the 
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bridge between CD28 signaling to NFκB pathway, which is considered to be the most 
relevant CD28 biochemical target [52].  
 
D. Acute lymphoblastic leukemia and Jurkat cells    
 Acute lymphoblastic leukemia (ALL) is a malignant disorder of lymphoid 
progenitor cells that are committed to differentiate into T- or B-cell lineage [53]. It is the 
most common childhood malignancies [53]. Although the cure rate in children is higher 
than 80%, relapsed ALL remains a leading cause of childhood mortality [53]. T precursor 
ALL comprises about 25% of ALL [54].  
 Jurkat cells were established from the peripheral blood of a 14-year-old boy with 
ALL during the first relapse in 1977 [54]. It was originally designated JM cell line after 
the patient's name [54]. It is a CD4+ T cell line and carries leukemia properties identical 
to fresh leukemic cells [54]. It is used in research as a producer of cytokine IL-2 [55]. IL-
2 is only produced by Jurkat cells treated with stimuli, such as phorbol esters with either 
lectins or monoclonal antibodies directly ligating TCR. My study will focus on Jurkat 
cells as a model system for IL-2 production and T cell activation.  
 
IV.  The Cytokine Interleukin-2    
A. Biological Function of IL-2  
 IL-2 was discovered in 1976 as a growth-promoting activity for T lymphocytes, 
and was the first Type I cytokine identified at the molecular level [56]. IL-2 is a four 
α−helical, secreted glycoprotein with a molecular weight of 15.5 kDa [48]. De novo 
synthesis of IL-2, followed by the ligand specific IL-2 receptor α chain (IL-2Rα), is the 
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immediate consequence of T cell activation [57]. IL-2Rα itself binds IL-2 with low 
affinity. IL-2Rβ combined with the common cytokine receptor γ chain (γc), binds with 
IL-2 with intermediate affinity. IL-2Rα/β/γc complex form a high affinity IL-2 receptor, 
and transduce IL-2 signals through the cytoplasmic domains of IL-2Rβ and γc [57]. IL-2 
signals activate at least three main signaling pathways, including PI3K/Akt, Ras-MAP 
kinase, and Janus kinase (Jak)/Stat5 pathways [57].  
 The in vitro function of IL-2 as a potent T cell growth factor has been well 
recognized. IL-2 is the most potent growth factor to stimulate T cell proliferation, 
survival and activation, and using monoclonal antibodies specific for IL-2 or IL-2R can 
efficiently inhibit T cell proliferation in vitro [58]. IL-2 also sensitizes activated T cells 
for activation-induced cell death (AICD) by Fas and Fas ligand induced apoptosis [59].  
 Later studies have revealed IL-2 as a pleiotropic cytokine that influences 
lymphocyte differentiation, immune responses and homeostasis [66, 67]. IL-2 or IL-2R 
knock-out mice develop severe autoimmunity instead of immune deficiency diseases [68, 
69] , indicating a crucial role of IL-2 in peripheral T cell tolerance. It has been proven 
that a failure of production of CD4+CD25+(also known as IL-2Rα) regulatory T cells is 
the underlying cause of the lethal autoimmunity in IL-2 deficient mice [70, 71].  Treg 
cells do not produce IL-2, but consistently express a high affinity IL-2 receptor [65] and 
depend highly on IL-2 signaling for their generation and homeostasis [66–68]. 
 Recent reports reevaluated the complex roles of IL-2 as a broad regulator of CD4+ 
T helper cell differentiation [67, 75, 76]. Although IL-2 does not specifically induce one 
type of helper T cells to differentiate, it modulates expression of cytokine receptors and 
transcription factors to either promote or inhibit helper T cell differentiation [69]. IL-2 
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induces the expression of IL-12 receptor β2 subunit (IL-12Rβ2) and of T-bet via Stat5 
pathway, thereby promoting Th1 cell differentiation [69]. For Th2 cells, IL-2 augments 
accessibility of IL4 gene chromatin [70] and increases the expression level of IL-4 
receptor α chain (IL-4Rα) [71]. However, the generation of Th17 cells is inhibited by IL-
2 signals [67, 70]. Since Treg and Th17 cells share a common requirement of cytokine 
TGF β for differentiation, IL-2 signals play a crucial role in the reciprocal balance 
between Th17 and Treg cells [73]. 
   
B. Regulation of IL-2 Expression 
 IL-2 is produced primarily by CD4+ T lymphocytes upon activation by antigen, 
although activated CD8+ cells and dendritic cells can also secrete small amounts of it [74]. 
The production of IL-2 is regulated at multiple levels, with most research emphasis on 
transcriptional regulation. Chromatin structure and epigenetic modification also play an 
important role in IL-2 gene regulation. In addition, posttranscriptional regulation, 
especially IL-2 mRNA stability, is also tightly controlled [46, 72, 73].  
 
Figure 5. The known regulatory elements and corresponding transcription factors identified 
in the IL-2 gene [74]. The figure is lifted from H. P. Kim, J. Imbert, and W. J. Leonard, 
Cytokine & growth factor reviews, vol. 17, no. 5, pp. 349–66, Oct. 2006.  
 
 
  
regulatory T cells. In a patient with T # B + NK-SCID (i.e.,
whereNKcells are absent andT cells diminished), expression
of the IL-2Rb chain was markedly decreased, but expression
of gc, Jak3, IL-15, and IL-15a all appeared normal [30].
2.3. gc-Deficient mice
Mice lacking expression of gc exhibit markedly
diminished thymic d velo ment, with thymuses only 1–
5% of normal size [31,32]. At birth, NK cells are absent and
mature B and T lymphocytes are markedly diminished,
indicating that gc is indispensable for the development of all
murine lymphocyte classes. Although activated CD4+ T
cells accumulate over time in gc-deficient mice, the CD8
+
population remains extremely small [31,33], suggesting that
mature CD4+ T cells respond to gc-independent mitogens,
whereas mature CD8+ T cells are dependent on gc for
proliferation and survival. B cells are greatly diminished,
and NK cells, gd int stinal intraepithelial lymphocytes,
dendritic epidermal T cells, peripheral lymph nodes, and
gut-associated lymphoid tissue are all absent in gc-deficient
mice. gc mutations in humans result in X-linked severe
combined immunodeficiency (XSCID), a disease that is
characterized by a profound decrease in circulating T
lymphocytes and NK cells [15,34,35].
The IL-2/IL-2R system is one in which responses are
dynamically regulated. This in part results from the
regulation of the components of this ligand/receptor system.
In the next sections, we describe the molecular mechanisms
that regulate expression of IL-2/IL-2 receptor components at
the transcriptional and post-transcriptional levels.
3. Regulation of the IL-2 gene
The majority of IL-2 is produced by activated CD4+ T
cells, although some IL-2 is secreted from CD8+ T cells as
well as at least transiently by dendritic cells [20,36]. The
expression of IL-2 is controlled at multipl levels, with most
investigation having focused on transcriptional regulation.
Multiple regulatory elements have been located in a minimal
enhancer region of approximately 300 bp that is located
immediately upstream of the transcription initiation site
(Fig. 2). This region is highly conserved (86% identical)
between humans and mice. Several important positive
regulatory elements have been identified in the IL-2 gene
(Fig. 2), and there is evidence that all binding sites in the IL-
2 promoter/enhancer need to be occupied by appropriate
transcription factors to ensure optimal transcription [37].
3.1. NFAT
Nuclear factor of activated T cell (NFAT) family proteins
serve as the critical transducers of the Ca2+ signal that is
associated with T-cell activation via the T cell receptor. NFAT
proteins are expressed con titutively but onl enter the
nucleus after their release from a cytoplasmic tethering site, a
process that requires the catalytic action of the Ca2+-
dependent phosphatase calcineurin. Five NFAT family
proteins have been identified, each of which is encoded by
a distinct g ne. Four of these (NFATc1,NFATc2, NFATc3 and
NFATc4) are calcium regulated, whereas NFAT5 is not.
NFATc1,NFATc2,NFATc3andNFAT5are expressedbycells
of the immune system, whereas NFATc4 is mainly expressed
outside of the immune system. A total of four NFAT binding
sites have been identified in the IL-2 promoter (Fig. 2) [38].
IL-2 gene expression was not altered in mice deficient in
either NFATc1 [39] or NFATc2 [40], suggesting the potential
redundancy of NFAT isoforms and the possible compensa-
tion by other NFAT family proteins in individual NFAT
knockout mice. Indeed, T cells lacking both NFATc1 and
NFATc2 cannot produce IL-2 [41], whereas T cells lacking
both NFATc1 and NFATc3 produce markedly less IL-2 [42],
indicating that NFATc1, NFATc2, and NFATc3 all positively
regulate IL-2 gene transcription.
3.2. AP-1
The AP-1 transcription factor is a dimer, composed of Jun
and Fos family proteins, most typically c-Jun and c-Fos
themselves. Activation of T cells through TCR-CD3
engagement leads to the activation of PKC-SEK1-JNK,
RAC-JNK, and RAS-RAF-ERK signaling pathways and
consequently the induction of AP-1. The RAS-ERK pathway
H.P. Kim et al. / Cytokine & Growth Factor Reviews 17 (2006) 349–366 353
Fig. 2. The known regulatory elements and corresponding transcription factors identified in the IL2 gene. The antigen receptor response elements (ARRE-1 and
ARRE-2) originally described by Durand et al. [83] are located, respectively,!95 to!60 and!283 to!243 relative to the transcription start site and contains
binding sites for NFAT, AP-1, Oct-1 [38].
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 An approximately 300bp minimal enhancer region upstream of the IL-2 gene 
transcription start site possesses consensus binding sites for several transcription factors, 
including NFAT, the activator protein 1 (AP-1), NFκB, and Octamer-binding protein 
(Oct), as well as additional regulatory sites such as the CD28 responsive element 
(CD28RE) [76]. All these positive regulatory elements need to be occupied by 
corresponding transcription factors for optimal IL-2 transcription (Figure 5) [74]. 
a. NFAT 
 The IL-2 promoter contains four binding sites for NFAT family transcription 
factors. Five NFAT family members have been identified, NFATc1 (also known as 
NFAT2 or NFATc), NFATc2 (also known as NFAT1 or NFATp), NFATc3, NFATc4 
and NFATc5, among which NFATc1, NFATc2 and NFATc3 all contribute to IL-2 gene 
regulation, with NFATc1 and NFATc2 the major players. Except NFATc5, the other four 
members are regulated by intracellular calcium levels. Calcium influx activates 
calcineurin, which dephosphorylates NFAT, leading to its nuclear translocation [77].  
 NFATc2 accounts for 80-90% of NFAT in resting T cells, and rapidly 
translocates to the nucleus following activation, thus playing an essential role in 
regulating an early stage response [78]. NFATc1 expression is induced following T cell 
activation, therefore regulating a later stage of IL-2 gene transcription. IL-2 gene 
expression was minimally altered in mice deficient in either NFATc1 [79] or NFATc2 
[80], while severely impaired in mice deficient in both [81].   
b. AP-1 
 AP-1 is a dimer of two basic region-leucine zipper proteins (bZIP), typically 
composed of Fos and Jun family proteins. c-Fos and c-Jun are the major components to 
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form AP-1 in the context of  regulating IL-2 gene [74]. c-Jun is the most potent 
transcriptional activator in the Jun family, and like other Jun proteins, can form both 
homo- and hetero- dimers. The Fos protein cannot homodimerize; they instead form 
heterodimers with Jun proteins and thereby enhance their DNA binding affinity [82].  
Both c-Fos and c-Jun contain transactivation potency after stimulation, and Fos-Jun 
heterodimers are more effective at DNA binding and transcriptional activation than Jun-
Jun homodimers [76]. 
 Signaling from TCR and CD28 activates JNK through both PKC and Rac 
mediated pathways [74]. JNK translocates to the nucleus and phosphorylates c-Jun at N-
terminal transactivation domain and results in a robust induction of c-Jun transactivation 
activity [83]. In addition to post-translational regulation, c-Jun activity is also regulated at 
the expression level. The promoter region of both c-Jun and c-Fos contain AP-1 binding 
sites, and are therefore regulated by AP-1 itself as a feed-forward mechanism [83]. The 
expression level of c-Fos is very low in naive T cells and T cell activation requires its de 
novo synthesis [84]. Signaling from TCR activates the Ras-Raf-ERK pathway and leads 
to the nuclear translocation of ERK to phosphorylate transcription factors, such as Elk1, 
to initiate the transcription of c-Fos [82].  
 AP-1 tends to cooperate with other transcription factors, such as NFAT, NFκB 
and Oct-1, to enhance their DNA binding affinity [46, 72]. Overexpression of Fos and 
Jun family protein augments NFAT-driven transcription [76], and a dominant -negative 
mutant of c-Jun inhibits NFAT transcriptional activity and prevents IL-2 gene 
transcription [85]. 
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c. NFκB 
 The IL-2 promoter contains two NFκB binding sites, with one located in the 
CD28RE, which is responsible for the responsiveness of IL-2 gene to CD28 
costimulation signal [74]. NFκB is the major target of CD28 signaling to activate IL-2 
transcription.  
 NFκB family is composed of two groups of proteins, NFκB proteins NFκB1 (p50) 
and NFκB2 (p52), and Rel proteins RelA (p65), RelB and c-Rel. NFκB1 and NFκB2 are 
synthesized as precursor proteins p105 and p100, respectively, and processed to yield 
mature proteins. The mature NFκB proteins contain Rel homology region (RHR), which 
is responsible for dimerization, DNA binding and interaction with inhibitors of κB (IκB), 
and also contains a nuclear localization signal (NLS) [86]. In addition to RHR, Rel 
proteins also contain transcriptional activation domains. Members of the two groups of 
proteins can form homo- or hetero-dimers as functional NFκB transcription factors [87]. 
p50-p50 and p52-p52 homo-dimers that lack transcriptional activation domains appear to 
repress transcription [86]. 
 In the resting state, NFκB dimers are sequestered by IκB proteins in the 
cytoplasm. Nuclear translocation of NFκB requires liberation from IκB, which depends 
on degradation of IκB by the proteasome [86]. Phosphorylation of IκB by the IκB kinase 
(IKK) complex marks it for ubiquitination. IKK is a multi-subunit complex with three 
core components, an adaptor protein IKKγ (ΝΕΜΟ), and a dimer of catalytic subunits 
IKKα/β [88]. Signaling from both TCR and CD28 merges to activate PKCθ, which 
directly phosphorylates Carma1, resulting in recruitment of Bcl10 and Malt1 to the 
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plasma membrane [89–91]. Carma1, Bcl10 and Malt1, often referred to as the CBM 
complex, mediate the activation of IKK complex through a mechanism that has not been 
fully understood [92], which at least involves ubiquitination of IKKγ [93] and 
phosphorylation of the catalytic subunit IKKβ [90, 91].  
 Besides the canonical IκB inhibitory mechanism, a non-canonical pathway 
depends on IKKα−mediated phosphorylation and processing of p100 associated with 
RelB, generating mature p52/RelB complex that is able to translocate to the nucleus [95].  
T cell activation mainly depends on the canonical pathway, with p50, RelA and c-Rel 
demonstrated targets of TCR or CD28 signaling [88]. Independent of IκB activity, 
phosphorylation of RelA is also important for its transcriptional activity, partially due to 
increased association with co-activators such as CREB binding protein (CBP)/p300 [96].  
Activated NFκB is generally composed of p50-p65 and p50-c-Rel. p65 probably 
mediates early time points of IL-2 gene transcription, and c-Rel contributes to later. c-Rel 
may be the major NFκB component mediating activation of the CD28RE [97].  
d. Oct 
 The IL-2 promoter contains two binding sites for Oct family proteins, and both 
sites contribute to IL-2 promoter activity [98]. The proximal Oct binding site is a 
composite element, to which Oct and AP-1 bind cooperatively [99]. Oct-1 is 
constitutively expressed, while Oct-2 is lymphocyte specific and its expression is induced 
by stimulation. The Jurkat T cell line was reported to lack Oct-2 protein but completely 
capable of IL-2 gene transcription [98].  
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e. CREB/CREM 
 The cAMP response element-binding protein (CREB) family consists of CREB, 
the cAMP response element modulator (CREM) and the activating transcription factor-1 
(ATF-1) [96, 97]. CREB family proteins bind to DNA as a dimer through the cAMP-
response element (CRE) [100]. IL-2 gene contains a CRE site at -180 region and 
mutation of this site almost completely abolishes IL-2 transcription [102]. T cells from 
transgenic mice expressing a dominant-negative form of CREB have a remarkable defect 
in proliferation and IL-2 production following activation [103].  
 Although sharing a high level of sequence homology with CREB, CREM either 
forms a homodimer or heterodimer with CREB and functions as a transcriptional 
repressor [104]. Increased expression of CREMα protein is proposed as the central cause 
of decreased IL-2 production in systemic lupus erythematosus (SLE) T cells [105]. 
Antisense CREM enhanced the accessibility of the IL-2 promoter to endonucleases and 
prevents the condensation of chromatin [106]. CREB transcriptional activity depends on 
phosphorylation of serine 133. Once phosphorylated, pCREB associates with its co-
activator, CBP, or its paralogue p300, to initiate transcription of target genes [100]. Later, 
pCREB is dephosphorylated, and CREM is produced and gradually replaces CREB to 
bind to the CRE site, resulting in downregulation of IL-2 gene [107].  
f. Sp1/Egr-1 
 An overlapping binding site for two zinc finger transcription factors, Sp1 and the 
early growth response protein-1 (Egr-1) is located immediately upstream of the distal 
NFAT/AP-1 binding site within the minimal IL-2 promoter [108]. In resting cells, only 
the constitutively expressed Sp1 protein binds to this region, whereas upon stimulation 
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the inducible protein Egr-1 replaces Sp1 and regulates IL-2 transcription via synergistic 
interaction with NFATc1 [109]. NGFI-A-binding protein 2 (NAB2) is recruited by Egr-1 
to IL-2 promoter and acts as a co-activator of T cell function by promoting Egr-1-
mediated IL-2 production [110]. 
g. GABP 
 The Ets family transcription factor GA binding protein (GABP) is a heterodimer 
of GABP α and β that binds to a distal enhancer of the IL-2 gene upstream of the 300bp 
minimal promoter region [111]. GABP contributes to IL-2 transcriptional activation 
through the ERK and JNK/SAPK pathways [111]. 
h. Transcriptional Repressors 
 Besides CREMα mentioned above, several other transcriptional repressors have 
been identified that contribute to restriction of IL-2 production and induction of T cell 
anergy.  
 The zinc finger E-box-binding protein (ZEB) 1 binds to the negative regulatory 
element NRE-A located at -100 upstream from the TSS [112]. ZEB1 recruits C-terminal-
binding protein (CtBP) 2 and histone deacetylase 1 (HDAC1) to repress IL-2 gene 
expression [113]. ZEB1 mediated transcriptional repression has been shown to contribute 
to the IL-2 gene silencing in activated Th2 cells [114].  
 The IL-2 promoter has two consensus binding sites for Ikaros, a component of the 
nucleosome remodeling and DNA methylation complex (NURD) [115]. Ikaros has been 
shown to repress IL-2 gene expression in CD4+ T cells through recruiting chromatin 
remodeling complexes [115] and therefore is required for anergy induction in CD4+ T 
cells [111, 112]. 
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 NFκB p50-p50 homodimers lack transactivation domains and act as 
transcriptional repressors [86]. In tolerant CD4+ T cells that do not produce IL-2, the 
intracellular level of p50 protein is increased [117] and predominant p50-p50 
homodimers bind to the NFκB  binding site of the IL-2 promoter instead of p50-p65 
[118]. 
i. Epigenetic Modification and Chromatin Remodeling 
 Epigenetic modifications of the IL-2 promoter region regulate the accessibility of 
the DNA to transcription factors and serve as a memory of the regulatory event [119]. 
Anti-CD3/CD28 stimulation of human CD4+ T cells induces active demethylation of a 
specific CpG site in the NFAT/Oct-1 binding element, and this modification is required 
for transcription factors binding to DNA and subsequent histone modification [119]. 
Upstream of the 300bp minimal enhancer, additional CpG methylation sites are also 
demethylated [120]. CpG demethylation seems to be stable once initiated, and therefore 
acts as an epigenetic memory to contribute to a more rapid response upon re-activation 
[115, 116]. 
 Chromatin structure at the IL-2 promoter region is also dynamically remodeled to 
become more accessible upon activation. The human IL-2 promoter can assemble a 
positioned nucleosome that occludes the binding of transcription factors to functional 
elements in resting state. The region becomes remodeled upon activation in Jurkat T cells 
[121]. Costimulation through both TCR and CD28 leads to histone acetylation and loss of 
cytosine methylation at the IL-2 promoter, accompanied by extensive remodeling of the 
chromatin [122].  
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j. Post-transcriptional Regulation 
  IL-2 mRNA level is not only regulated at the level of transcriptional initiation, but 
also mRNA stability. IL-2 mRNA contains several AU-rich (AUUUA) elements (AREs) 
in its 3' untranslated region (UTR), which is known as a common indicator of mRNA 
instability [123]. After stimulation with anti-CD3/CD28 antibodies, the relatively short 
half-life of IL-2 mRNA is significantly prolonged [124]. TCR and CD28 costimulation 
mediated regulation of mRNA stability requires the 3' [125] and 5' -UTR [126] as well as 
sequences within the coding region [127].   
 ARE directed mRNA decay can be positively or negatively regulated in response 
to extracellular stimuli. NF90 is an RNA binding protein that recognizes and binds AREs 
in 3'-UTR region and therefore decelerates IL-2 mRNA degradation [125]. NF90 
localizes in the nucleus in resting Jurkat cells, and translocates to the cytoplasm in 
response to stimulation where it binds to mRNA [125]. Nuclear export of NF90, 
mediated by Akt-dependent phosphorylation in response to CD28 costimulation, is 
required for IL-2 mRNA stabilization [121, 124]. 
 Another signaling pathway that contributes to IL-2 mRNA stabilization is the 
JNK pathway [126], which functions through a JNK response element (JRE) in the 5'-
UTR that binds to two RNA binding proteins, nucleolin and YB-1 [129]. CD28 signaling 
also acts through sequences within the coding region of exon 2 and exon 4 to stabilize the 
IL-2 mRNA [127]. In contrast, CD28 signaling, at later times, enhances IL-2 mRNA 
decay through sequences localized between exon 3 and the stop codon [127], ensuring a 
tightly regulated response. 
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C. Diseases Related to Abnormal Activation of T Cells  
 Autoimmunity is a loss of tolerance to multiple self-antigens. SLE is an 
autoimmune disease characterized as autoantibody production and inflammatory cell 
infiltration into target organs [130]. T cells play a critical role in the pathogenesis of SLE 
as they regulate and assist autoreactive B cells. T cells from SLE patients resemble naive 
or anergic T cells in certain ways, but at same time carry characteristics reminiscent of 
activated T cells [130]. In SLE T cells, the TCR ζ chain is replaced by the Fc receptor 
(FcR) γ chain, which recruits spleen tyrosine kinase (Syk) instead of ZAP-70 [131]. Syk 
is a more efficient signal transducer and results in a hyper-phosphorylation of 
downstream signaling molecules [132] and increased calcium influx [133]. Increased 
calcium influx leads to abnormally high NFAT dephosphorylation, which accounts for 
enhanced transcription of multiple target genes such as CD40L (CD154). The interaction 
of CD40L on the surface of T cells and CD40 on B cells activates B cells and facilitates 
autoantibody production in SLE [131]. However, SLE T cells have a reduced ability to 
produce IL-2, despite the increased NFAT activity [130].  Several key transcription 
factors that regulate IL-2 expression have decreased expression levels in SLE T cells, 
including Rel-A [134], c-Fos [135] and CREB [136], while the transcription repressor, 
CREMα, has increased activity [106]. Impaired IL-2 production is responsible for 
decreased activation-induced cell death and extensive survival of autoreactive 
lymphocytes [137], as well as reduced Treg cell function [138].  
 Treg cells are essential for the maintenance of self-tolerance and immune 
homeostasis, and therefore play a protective role in autoimmune diseases. Defects in Treg 
numbers and function have been shown in human autoimmunity and a restoration in 
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model systems can prevent and reverse disease [139]. Another subset of T helper cells, 
Th17 cells, and their effector molecules, actively participate in the pathogenesis of 
multiple autoimmune diseases, such as SLE and rheumatoid arthritis (RA) [140]. 
 Allergic diseases are characterized as a hypersensitive response toward an 
innocuous antigen, which comprise two main components of the immune response: an 
abnormal polarization of naive Th0 cells to differentiate into Th2 phenotype and class 
switching to IgE in B lymphocytes [31]. T cell activation and cytokine secretion are 
essential mediators in allergy. A preferential skewing to expansion of the Th2 
lymphocytes is the crucial forerunner to the pathogenesis of allergic diseases [141]. 
Excessive Th2 cytokine expression and a reduced production of Th1 cytokine IFNγ is 
noted in atopic disease [141]. Therefore, preventing or reversing the process of abnormal 
Th2 polarization has been a focus for the development of new therapeutic strategies to 
control allergies and asthma [141]. Recently, IL17-producing Th17 cells have been 
shown to play a role in driving cytokine production, neutrophil recruitment and airway 
hyperresponsiveness in steroid-resistant asthma [142].  The cytokine IL-17 family has 
increased levels in asthma and COPD and promotes airway neutrophilia and allergic 
responses [142]. In contrast, Tregs have shown reductions in numbers and capacity to 
suppress effector T cells and Th2 cytokine production in asthma [143], implicating their 
role in modulation and suppression of allergic airway responses.  
 
D. Inhibitors of T cell Activation and Their Therapeutic Uses  
 Inhibitors of T cell activation are commonly used as immunosuppressants in 
transplantation, autoimmune diseases, and allergic asthma. Glucocorticoids (GCs) are the 
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first immunosuppressants used in transplantation [144]. By binding to GC receptors, GCs 
inhibit AP-1 and NFκB pathways, thus blocking IL-2 production in T cells [144]. 
Although very potent, they are the least selective inhibitors that affect lymphocytes as 
well as non-lymphoid cells, therefore causing severe side effects [145].  
 The most well characterized inhibitors specific for T cell activation are 
cyclosporin A (CsA) and tarolimus (FK506). They bind to specific immunophilins in T 
cells and the drug-immunophilin complexes block activation of the calcium calmodulin-
dependent serine/threonine phosphatase calcineurin, thus inhibiting NFAT regulated IL-2 
expression [146]. These two drugs have been very useful working either alone, or in 
combination with GCs for lowering GC doses and reducing side effects [144]. CsA is 
also commonly used in research for its ability to inhibit IL-2 production and T cell 
activation.   
 Another group of T cell inhibitors target the mammalian target of rapamycin 
(mTOR), such as rapamycin (or sirolimus) and everolimus [144]. mTOR is a 
serine/threonine protein kinase that acts downstream of IL-2 receptor engagement to 
regulate mRNA translation [147]. These inhibitors exert anti-inflammatory effects by 
blocking IL-2 post-receptor signaling and subsequently inhibiting T cell proliferation 
[136, 140, 141]. mTOR inhibitors and calcineurin inhibitors are currently used in 
combination to prevent transplant rejection [150].   
 Other inhibitors targeting various surface and intracellular signaling molecules in 
T cells are under investigation for their potential use in transplantation and anti-
inflammation. For example, R788, a specific Syk inhibitor, ameliorated both skin and 
kidney symptoms in lupus prone mice [151]. AEB071, an early-T cell activation inhibitor 
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selectively targeting PKC, showed promising potential for immunosuppression in organ 
transplantation [150].  
  
V.  B lymphocytes  
A. B cell development and function  
 B cells develop from HSC in bone marrow [31]. The process of B cell 
development requires the specific environment provided by bone marrow stromal cells 
[31]. The lineage commitment is largely regulated by a combination of transcription 
factors and signaling pathways [152]. Specifically, Ikaros controls the development of 
common lymphoid progenitors (CLP) and Pax5 is crucial in both activating B cell 
specific genes and repressing lineage inappropriate genes [152].  The early 
developmental stages can be divided into Pro, Pre, Immature and Mature B cells, with the 
first three stages occur in bone marrow (Figure 6) [31]. Each stage is marked by the 
rearrangement and expression of immunoglobulin (Ig) genes to make functional B cell 
receptors (BCR) or their surrogates. Signal transduction by BCR or their surrogate is 
critical for progression through multiple developmental checkpoints [153]. Ordered Ig 
gene rearrangement ensures that each immature B cell bears antigen receptors of a single 
specificity and generates a diverse repertoire of B-cell receptors for antigen recognition 
[152]. Immature B cells, characterized by the expression of membrane IgM, migrate to 
the periphery where they undergo further maturation into naive mature B cells [153].  
 Once encountering antigen in the periphery, naive B cells proliferate and 
differentiate into antibody secreting plasma cells. Binding of an antigen causes BCR to 
crosslink, triggering signal transduction pathways that result in changed gene expression 
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in the nucleus [154]. As a result, B cells enter the cell cycle, migrate to primary lymphoid 
follicles and ultimately form a germinal center [31]. Some germinal center B cells 
differentiate into plasmablasts and then into plasma cells, which are responsible for long-
lasting antibody secretion. Others differentiate into memory B cells that provide a rapid 
response when the host reencounters the same antigen [31].  
 
 
Figure 6. Hematopoiesis. HSC: Hematopoietic stem cell; CLP: common lymphoid 
progenitor; CMP: common myeloid progenitor; GMP: granulocyte-monocyte progenitor; 
MEP: megakaryocyte–erythroid progenitor; DN: double negative; DP: double positive.  
 
B. Diffuse large B-cell lymphoma and OCI-LY18  
 Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-
Hodgkin's lymphoma (NHL) in adults, accounting for approximately 40% of NHL [155].  
DLBCL is a heterogeneous mature B-cell malignancy. Gene expression profiling has 
identified two molecularly distinct forms of DLBCL, one germinal center B-like DLBCL 
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and the other activated B-like DLBCL [149, 150].  Approximately 30-40% of DLBCL 
carry BCL-6 gene rearrangements, resulting in deregulation of the cell cycle and 
enhanced proliferation; about 20% carry BCL-2 gene rearrangements, resulting in 
inhibition of apoptosis [151, 152] 
 OCI-LY18 (Ontario Cancer Institute-LY18) is a germinal center B-like DLBCL 
cell line. It was established from the pleural fluid of a 56-year-old male patient, who was 
diagnosed with a high grade NHL of diffuse large cell immunoblastic type in 1988 [159].  
LY18 cells carry chromosome translocations involving bands 8q24, 14q32 and 18q21, 
which leads to a rearrangement of the MYC gene [159] and also carry p53 and BCL-2 
gene rearrangements [160]. My study uses LY18 cells as a model system for mature B 
cell malignancy.  
 
VI.  Monocytes  
A. Monocyte development and function  
 In addition to common lymphoid progenitors, pluripotent HSC also give rise to 
common myeloid progenitors (CMP). CMP further develop into granulocyte-monocyte 
progenitors (GMP) in bone marrow, which in turn give rise to neutrophils, eosinophils, 
basophils and monocytes (Figure 6) [31]. Differentiation is governed by transcriptional 
regulation of lineage specific genes. Specifically, PU.1 and CCAAT/enhancer-binding 
proteins (C/EBPs) regulate the progression of HSC to CMP, then further to the GMP 
branch, respectively [161]. Increased PU.1 activity further directs GMP to commit to the 
monocytic lineage [161].  
	  	   34	  
 Monocytes are a heterogeneous population of cells with subgroups that differ in 
size, surface marker expression and function [162]. Human monocytes are divided into 
two subsets based on the expression of surface markers CD14 and CD16 (FcγR III) [155, 
156]. CD14++CD16- monocytes are the most prevalent monocyte subset, constituting 
approximately 90% of total monocytes in human and are therefore referred to as classical 
monocytes [155, 157]. Classical monocytes express the CC-chemokine Receptor 2 
(CCR2), which plays a key role in mediating monocyte migration from bone marrow into 
the circulation in response to infection or inflammation [163]. CD16+ monocytes are 
smaller in size and less prevalent. They increase in frequency during infections and are 
also referred to as proinflammatory monocytes [164].  
 Monocytes have an essential role in innate immune defense against diverse 
pathogens, including bacteria, parasites, fungi and viruses, and also contribute to the 
adaptive immune response [164]. At the site of infection, monocytes mature into 
macrophages or inflammatory dendritic cells [157, 158]. Macrophages contribute to 
pathogen elimination mainly by phagocytosis. Macrophages and dendritic cells also 
function by antigen presentation and therefore help activate T cells [164].    
 
B. U937 cells  
 The U937 cell line was established from a 37-year-old male patient with 
histiocytic lymphoma in 1976 [166]. The cell line was identified as having a histiocytic 
origin by its capacity for lysozyme production and strong esterase activity [166]. The 
U937 cell line is one of the few established human cell lines exhibiting monocytic 
characteristics [167]. They can be induced to mature macrophage-like cells in culture 
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[160, 161]; therefore commonly used the as a model for differentiation of monocytes and 
macrophages in vitro. My study uses U937 cell line as a model system for monocytic 
malignancy.  
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MATERIAL AND METHODS 
 
Antibodies and Reagents 
 Anti-human IL-2 and anti-goat IgG- horseradish peroxidase (HRP) antibodies 
were obtained from R&D systems (Minneapolis, MN). Anti-β-actin antibody was 
obtained from Sigma-Aldrich (St. Louis, MO). Anti-mouse Ig-G was obtained from 
Jackson ImmunoResearch (West Grove, PA). Anti-human CD3 antibody was from 
eBioscience (San Diego, CA). Anti-human CD28 and anti-human caspase 8 antibodies 
were purchased from BD Biosciences (San Jose, CA). Anti-mouse IgG-HRP and anti-
rabbit Ig-G-HRP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Anti-Rel-A antibody was from EMD Millipore (Billerica, MA) and all other antibodies 
were from Cell Signaling (Danvers, MA). APO-BRDUTM Kit, FITC-BrdU Flow Kit, 
FITC-conjugated anti-active caspase 3 monoclonal antibody, Fc Block, and BD 
Cytofix/CytopermTM Kit were all obtained from BD Biosciences. Immobilon-P 
membrane was obtained from EMD Millipore. ECL reagents were obtained from 
Kirkegaard and Perry Laboratories (Gaitherburg, MD). Lympholyte M was purchased 
from Accurate Chemical and Scientific (Westbury, NY). Protein Transport Inhibitor 
(Containing Monensin) was purchased from BD Biosciences. Cyclosporin A 
Tolypocladium inflatum was obtained from Calbiochem, EMD Millipore. Primers, NFAT 
and AP-1 binding sites of the human IL-2 promoter were synthesized by Integrated DNA 
Technologies (Coralville, Iowa). NFAT, NFκB and Oct-1 consensus oligonucleotides 
were purchased from Santa Cruz Biotechnology. RETROscript Kit, TURBO DNase-free 
Kit, RNaseZap wipe and spray were from Life Technologies (Grand Island, NY). 
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RealMasterMix SYBR ROX was purchased from 5 Prime (Gaithersburg, MD). RPMI 
1640 was purchased from Cellgro, Corning (Manassas, VA). T4 polynucleotide kinase 
was obtained from New England Biolabs (Ipswich, MA). [γ-32P] ATP was obtained from 
Perkin Elmer (Waltham, MA). All other chemicals were obtained from Sigma-Aldrich. 
 
T Lymphocyte Isolation, Cell Culture and Stimulation  
 BALB/cJ mice were obtained from The Jackson Laboratory (Bar Harbor, ME) 
and housed at Boston College. Mice were cared for and handled at all times in 
accordance with National Institutes of Health and Boston College guidelines. Mouse T 
lymphocytes were isolated from mouse spleen by sedimentation on Lympholyte M 
followed by negative selection using Mouse Pan T cell Isolation Kit II (Miltenyi Biotec, 
Auburn, CA) according to the manufacturer's protocols. Peripheral venous blood was 
obtained from healthy volunteers for each study and peripheral blood mononuclear cells 
(PBMCs) were isolated using Ficoll-Paque according to the Miltenyi online protocol. 
Total human primary T cells or CD4+ T cells were further separated by negative selection 
using Human Pan T Cell Isolation Kit II or Human CD4+ T Cell Isolation Kit II (Miltenyi 
Biotec, Auburn, CA) according to the manufacturer's protocol. The Jurkat cell line (E6-1) 
was kindly provided by Dr. Charles Hoffman (Boston College, MA). The OCI-LY18 
(LY18) cell line was kindly provided by Dr. Raju Chaganti (Memorial Sloan-Kettering 
Cancer Center, New York, NY). The U937 cell line was obtained from American Type 
Culture Collection (Manassas, VA). Jurkat cells, LY18 cells, U937 cells and mouse 
primary T cells were cultured in RPMI 1640 (Atlanta Biologicals, Norcross, GA) 
supplemented with 10 mM HEPES (pH 7.5), 2 mM L-glutamine, 50 µM 2-
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mercaptoethanol, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% heat-inactivated 
fetal bovine serum (FBS) (Atlanta Biologicals, Norcross, GA) at a density of 5 × 105-1 × 
106 cells/ml. Human T lymphocytes were cultured in RPMI 1640 with 2% heat-
inactivated human AB serum and all the supplements listed above except FBS at a 
density of 1 × 106 cells/ml. Cells were maintained in a 37 oC humidified incubator at 5% 
CO2 at 95% humidity. T cells were stimulated by the combination of 0.5 µg/ml 
phytohaemagglutanin (PHA) and 50 ng/ml phorbol myristate acetate (PMA), or 20 ng/ml 
PMA and 1 µM Ionomycin. For antibody stimulation of human primary T cells, 10 µg/ml 
anti-mouse antibody diluted in PBS was coated on 96-well flat-button plate by incubating 
at 37 oC for one hour. The plate was washed twice with PBS, followed by incubating 1 
µg/ml anti-CD3 antibody for another hour at 37 oC and washing with PBS. Human 
primary T cells (0.2 × 106) were plated in 0.2 ml media as stated above with 1 µg/ml anti-
CD28 antibody supplemented in solution. 
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
 To measure the concentration of IL-2 or other cytokines secreted by cells, Jurkat 
cells or primary T cell from human or mouse were cultured in 96-well plate at 1 × 106 /ml 
with each treatment condition in duplicates. At the end of treatment, the plate was 
centrifuged at 300 ×g for 3 minutes at 4 oC. Supernatants were collected and subjected to 
ELISA according to the manufacturer's instruction provided by Quantikine Human IL-2 
kit from R&D Systems (Minneapolis, MN) or by Human Th1/Th2/Th17 Cytokines 
Multi-Analyte ELISArray kit from SABiosciences (Qiagen, Valencia, CA). 
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Nuclear Extraction for Western Blotting   
 Jurkat cells (5 × 106) or mouse primary T cells (1 × 107) were washed with PBS 
and incubated on ice for 10 minutes in 150 µl hypotonic buffer (20 mM HEPES and 3 
mM MgCl2) supplemented with freshly added 2 mM DTT, 1 mM PMSF, and protease 
inhibitor cocktail. At the end of the incubation, Nonidet P-40 was added to the mixture at 
a concentration of 0.06%. The mixture was gently vortexed for 5 seconds and subjected 
to centrifugation for 3 minutes at 300 × g at 4 oC. The supernatant was collected and 
saved as raw cytosolic fraction. The pellet was washed with ice-cold PBS and centrifuged 
for 3 minutes at 300 × g. After carefully removing all supernatant, the pellet was 
resuspended in 50 µl of RIPA buffer (20 mM Tris-HCl (pH 7.5),  150 mM NaCl, 1% 
Nonidet P-40, 1% sodium deoxycholate, and 0.1% SDS) supplemeted with freshly added 
2 mM DTT, 10 mM PMSF, and protease inhibitor cocktail, sonicated for 5 seconds and 
incubated on ice for 20 minutes. After centrifugation at 16,000 × g at 4 oC for 10 minutes, 
the supernatant was saved as nuclear fraction. The raw cytosolic fraction was further 
centrifuged at 16,000 × g at 4 oC for 10 minutes, and the supernatant was saved as 
cytosolic fraction.  
 
Whole Cell Extraction for Western Blotting  
 Jurkat cells (4 × 106) or mouse primary T cells (1 × 107) were washed with PBS 
and centrifuged at 626 × g at 4 oC for 8 minutes. The pellet was lysed on ice for 20 
minutes in 50 µl cyclin lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 20 mM 
EDTA (pH 8), and 0.5% Tween-20) supplemented with freshly added 1 mM DTT, 1 mM 
PMSF, 1 mM Okadaic acid, 1 mM Na3VO4, 10 mM β-glycerophosphate, and 10 mM 
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NaF. The mixture was subjected to centrifugation at 16,000 × g at 4 oC for 20 minutes, 
and the supernatant was collected and saved as whole cell extract at -80 oC. 
 
Western Blotting 
 Nuclear extracts or whole cell extracts were obtained from Jurkat cells or primary 
T cells. Lysate protein was separated by electrophoresis through a 15% polyacrylamide 
SDS-gel (SDS-PAGE) for IL-2 detection or 8% or 10% for other proteins and transferred 
to Immobilon-P membrane. The membrane was blocked in TBS-T (20 mM Tris (pH 7.6), 
137 mM NaCl, and 0.05% Tween-20) containing 5% nonfat dry milk for 1 hour and 
incubated overnight at 4 oC with primary antibody in TBS-T, washed and then incubated 
with a 1:2500 dilution of secondary IgG-coupled horseradish peroxidase antibody for 1 
hour and developed by enhanced chemiluminescence (ECL). Autoradiograms were 
scanned with Adobe Photoshop 7.0 (Adobe Systems, Inc., San Jose, CA) and the mean 
density of each band was analyzed by the ImageJ program (NIH, Bethesda, MD). 
 
Reverse Transcription and Real-Time PCR   
 Jurkat cells (6 × 106) or human primary T cells (1 × 107) were used for each 
treatment. Cells were centrifuged at 626 × g for 8 minutes at 4 oC and cell pellets were 
washed with PBS. RNA extraction was done following the protocol provided by Qiagen 
RNeasy mini kit (Hilden, Germany). The working area was RNase free after RNaseZap 
treatment. RNA was treated with DNase I at 37 oC for 30 minutes to digest remaining 
DNA. The concentration of RNA was determined by measuring the absorbance at 260 
nm in a spectrophotometer. The purity of RNA was estimated by the ratio of the readings 
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at 260 nm and 280 nm. At each reverse transcription reaction, 2 µg of RNA was used to 
generate cDNA using RETROscript Kit according to the manufacturer's instruction. Real-
time PCR was performed using the RealMasterMix SYBR ROX on a Mastercycler ep 
realplex2 real-time PCR instrument (Eppendorf, Germany). Amplification conditions 
were as follows: 95 oC 3 minutes, followed by 40 cycles of 95 oC 15 seconds, 60 oC 90 
seconds, 72 oC 15 seconds. For mRNA stability assay, Jurkat cells were stimulated with 
PHA and PMA for 4 hours before adding 1 µg/ml Cyclosporin A to inhibit IL-2 
transcription. Total RNA was isolated at each time point and reverse transcribed to 
cDNA. The level of IL-2 mRNA was determined by real-time PCR following 
normalization to a house-keeping gene, β-actin, with IL-2 mRNA levels in media cells as 
the calibrator. Primers were obtained from literature [169]. 
IL-2 primers:  forward: 5’- GAATGGAATTAATAATTACAAGAATCC-3’;  
reverse: 5’-GACACTGAAGATGTTTCAGTTCTGT-3’.  
β-actin primers:  forward: 5’-TCACCCACACTGTGCCCATCTACGA-3’;  
reverse: 5’-CAGCGGAACCGCTCATTGCCAATGG-3’.  
 
Viability Assay and Cell Cycle Analysis 
 For viability assays, propidium iodide stock solution was diluted at 1 µg/ml in 
PBS. Approximately 1 × 105 cells were directly added to 500 µl propidium iodide 
staining solution. Cells were kept on ice protected from light until analysis by flow 
cytometry. For cell cycle analysis, 0.5 to 1 × 106 cells were washed twice with ice-cold 
PBS, resuspended in 0.5 ml staining solution (PBS containing 0.1% Triton X-100, 100 
µg/ml RNase IIIA and 50 µg/ml propidium iodide) and incubated at 37 oC for 30 minutes 
	  	   42	  
in dark. DNA content was measured by flow cytometry using a FACSCanto cytometer 
and BDFACS Diva software (BD Biosciences, San Jose, CA).  
 
BrdU Incorporation  
 BrdU was added to U937 cell culture at a final concentration of 20 µM for 24 
hours before cells were collected. For each condition, 2 × 106 cells were collected and 
washed with PBS. FITC-BrdU labeling was performed according to the manufacturer's 
instruction (BD Biosciences) and DNA synthesis was measured by flow cytometry using 
a FACSCanto cytometer and BDFACS Diva software (BD Biosciences, San Jose, CA).  
 
Terminal Deoxynucleotidyltransferase dUTP Nick End Labeling (TUNEL) Assay 
 At each time point, LY18 or U937 cells (1 × 106) were collected, washed with 
PBS, fixed and permeabilized using BD Cytofix/CytopermTM Kit following 
manufacturer's instruction (BD Biosciences). Samples were stored at 4 oC until ready to 
be labeled. TUNEL assays were performed using APO-BrdUTM kit following 
manufacturer's instruction (BD Biosciences). Apoptotic cells were labeled with FITC-
conjugated anti-BrdU antibody. Samples were analyzed by flow cytometry using a 
FACSCanto cytometer and BDFACS Diva software. 
 
Caspase 3 Staining by Flow Cytometry 
 At each time point, LY18 or U937 cells (1 × 106) were collected, washed with 
PBS, fixed and permeabilized using BD Cytofix/CytopermTM Kit following 
manufacturer's instruction (BD Biosciences). Samples were stored at 4 oC until ready to 
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be labeled. For caspase 3 labeling, cells were resuspended in 100 µl Perm/Wash solution 
(BD Cytofix/CytopermTM Kit) plus 2 µl Fc block and incubated at 4 oC for 20 minutes. 
After washing with 100 µl Perm/Wash, cells were resuspended in 100 µl Perm/Wash plus 
20 µl FITC-conjugated anti-active caspase 3 antibody and incubated at 4 oC for 1 hour. 
Cells were then washed once with Perm/Wash, resuspended in 500 µl Perm/Wash 
solution and analyzed by flow cytometry. 
 
Nuclear Extraction and Electrophoretic Mobility-Shift Assay (EMSA)  
 Jurkat cells (1 × 107) were washed with PBS and incubated on ice for 10 minutes 
in 5 ml Hypotonic Buffer (20 mM HEPES and 3 mM MgCl2) supplemented with freshly 
added 2 mM DTT, 1 mM PMSF, and protease inhibitor cocktail. The mixture was 
subjected to centrifugation at 626 × g for 8 minutes. The supernatant was saved as 
cytoplasmic fraction. The pellet was resuspended in 50 µl of High Salt Buffer C (30 mM 
HEPES, 25% glycerol, 450 mM NaCl, 0.3 mM EDTA and 12 mM MgCl2) supplemented 
with 6 mM DTT, 1 mM PMSF and protease inhibitor cocktail, and incubated on ice for 
30 minutes. After centrifugation for 10 minutes at 16,000 × g, the supernatant was 
collected and diluted with an equal volume of Buffer D (30 mM HEPES, 25% glycerol, 
0.3 mM EDTA and 12 mM MgCl2) with the same supplements as buffer C. All nuclear 
extracts were diluted to 2 mg/ml with the 1:1 mixture of buffer C and D and stored at -
80oC. The DNA probes were radiolabeled with [γ-32P] ATP by T4 polynucleotide kinase. 
5 µl of nuclear extracts were incubated with 3 µl radiolabeled dsDNA probe 
(10,000cpm), 1 µg of poly (dI/dC) and 6 µl of dH2O to a total volume of 15 µl for 20 
minutes at room temperature. The reaction mixture was then subjected to separation in 
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6% nondenaturing gel. The dried gel was autoradiographed over night at -80 oC. For 
supershift assays, the nuclear proteins were incubated with 4 µg specific antibodies at 4 
oC for 10 minutes before the probe, poly (dI/dC) and dH2O were added. The reactions 
were further conducted for another 20 minutes at room temperature. The sequences of 
distal NFAT binding site of the human IL-2 promoter [170] and AP-1 binding site of the 
human IL-2 promoter [171] were obtained from literature. The sequences of the probes 
used were:  
Distal NFAT binding site of the human IL-2 promoter:  
5’-GATCGGAGGAAAAACTGTTTCATACAGAAGGCGT-3’;  
NFAT consensus oligonucleotide: 5'-CGCCCAAAGAGGAAAATTTGTTTCATA-3' 
NFκB consensus oligonucleotide: 5’-AGTTGAGGGGACTTTCCCAGG-3’. 
AP-1 binding site of the human IL-2 promoter: 5'- TTCCAAAGAGTCATCAG-3' 
Oct-1 consensus oligonucleotide: 5’-TGTCGAATGCAAATCACTAGAA-3’ 
 
 
 
 
 
 
 
 
 
 
 
  
	  	   45	  
 
 
 
 
 
 
 
 
 
 
 
 
Chapter One 
 
An in vitro PDE7 inhibitor inhibits IL-2 gene expression in 
activated T cells by repressing NFκB and NFAT-mediated 
transcription 
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RESULTS 
 
BC12 inhibits IL-2 protein production in activated Jurkat cells  
 The Jurkat T cell line is a common model for studying T cell signaling and IL-2 
production [1, 2]. To begin to evaluate the potential immunomodulatory effects of the 
novel in vitro PDE7 inhibitor BC12, we first examined extracellular IL-2 secretion in 
activated Jurkat cells by ELISA (Figure 1). Jurkat cells were stimulated by a combination 
of 0.5 µg/ml phytohemagglutinin (PHA) and 50 ng/ml phorbol 12-myristate 13-acetate 
(PMA). PHA is a plant lectin that binds to cell membrane glycoproteins including TCR-
CD3 complex, causing extensive crosslinking of the TCR receptors and triggering 
signaling [172]. PMA is a structural analog of diacylglycerol, and therefore can stimulate 
T cells by activating PKC [172]. A combination of PHA and PMA increased IL-2 
secretion, whereas the DMSO control had a minimal effect on PHA/PMA induced IL-2 
secretion (Figure 1). At 24 hours of treatment, BC12 inhibited IL-2 production to 74% 
compared to DMSO control at a dose of 1 µM, 15% at 5 µM, and 2% at 10 µM (Figure 
1). Cells with the same treatments were analyzed for cell viability by propidium iodide 
staining and flow cytometry. Compared to cells treated with PHA/PMA/DMSO control, 
which resulted in 93% of viable cells, BC12 in combination of PHA/PMA moderately 
reduced cell viability to 85% at 1 µM, 81% at 5 µM, and 65% at 10 µM (Figure 2). 
Therefore, inhibition on IL-2 production by activated Jurkat cells cannot be attributed to 
reduced cell viability.  
 To examine the timing of inhibitory effects on IL-2 production by BC12, Jurkat 
cells were stimulated by PHA/PMA and/or treated with BC12 simultaneously for various 
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lengths of time (Figure 3). Following PHA/PMA stimulation, Jurkat cells exhibited a 
time-dependent secretion of extracellular IL-2 starting from 3-6 hours after stimulation. 
Treatment with 10 µM of BC12 nearly abolished IL-2 secretion completely from the 
beginning and the inhibitory effect was maintained over time up to at least 24 hours 
(Figure 3). 
 Reduced levels of IL-2 secretion could be due to either decreased endogenous IL-
2 protein production or impaired secretion. To examine the endogenous cytokine level, 
monensin, a Golgi inhibitor was used to block IL-2 secretion in Jurkat cells. Accumulated 
intracellular IL-2 protein was detected by Western blotting (Figure 4A). As expected, 
unstimulated or DMSO treated Jurkat cells did not express detectable IL-2. PHA/PMA-
stimulated Jurkat cells expressed IL-2 at 12 hours. Incubation with 10 µM of BC12 in 
addition to PHA/PMA significantly decreased IL-2 expression (Figure 4A). Of note, the 
effect of monensin to block IL-2 secretion was confirmed by ELISA (Figure 4B). Jurkat 
cells stimulated by PHA/PMA in the presence of monensin had a significantly lower IL-2 
secretion level than in the absence of monensin (Figure 4B).  
 In summary, we investigated the immunomodulatory effects of BC12 on IL-2 
production in activated Jurkat cells and discovered that BC12 inhibited IL-2 protein 
production in a dose dependent manner. The inhibitory effect started at the beginning of 
de novo protein synthesis and was maintained up to at least 24 hours.  
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BC12 inhibits IL-2 gene expression in activated Jurkat cells through transcriptional 
repression 
 To further evaluate the role of BC12 on IL-2 production, we sought to directly 
assess relative mRNA levels of IL-2 in activated Jurkat cells by semi-quantitative reverse 
transcription PCR (Figure 5).  Following PHA/PMA stimulation, IL-2 mRNA levels 
started to increase after 1 hour, peaked at approximately 5 hour and then declined. 
Treatment of Jurkat cells with BC12 simultaneously blocked IL-2 mRNA expression 
(Figure 5).  
 IL-2 mRNA is regulated both at the transcriptional and mRNA degradation levels 
[123]. Upon stimulation, IL-2 mRNA is not only upregulated at transcriptional initiation, 
but also has a prolonged half-life [123]. To further investigate the mechanism of 
inhibition by BC12 on IL-2 mRNA level, we performed mRNA stability assays to assess 
the degradation rate of IL-2 mRNA (Figure 6). Jurkat cells were stimulated with 
PHA/PMA for 4 hours to initiate IL-2 gene transcription. The fold induction of IL-2 
mRNA after 4 hours of stimulation was 1054 compared to unstimulated Jurkat cells. 
After the initial induction of mRNA expression, cyclosporin A (CsA) was used to inhibit 
IL-2 transcription [173]. CsA blocks activation of the calcium calmodulin-dependent 
serine/threonine phosphatase calcineurin, therefore inhibiting NFAT regulated IL-2 
expression [146]. Without CsA, mRNA levels in DMSO treated cells continued to 
increase for another hour (total 5 hours of stimulation) and then decreased, consistent 
with the results noted in Figure 5 (Figure 6, DMSO). In the presence of CsA, IL-2 mRNA 
levels became a function of degradation rate and time. In the absence of BC12, IL-2 
mRNA levels decreased to about 70% of the starting point after 1 hour, and about 40% 
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after 2 hours (Figure 6, CsA). Importantly, BC12 did not increase the rate of mRNA 
turnover beyond that observed for CsA alone (Figure 6, CsA+BC12). Of note, adding 
BC12 reduced IL-2 mRNA levels compared to the DMSO control, even when added after 
IL-2 mRNA expression has already been induced (Figure 6, BC12).  
 Taken together, these results indicate that BC12 blocks IL-2 secretion by 
inhibiting IL-2 gene transcription, while mRNA degradation rate remains unaffected.  
 
BC12 inhibits IL-2 expressions not through PDE  
 BC12 was first identified as an in vitro PDE7 inhibitor (unpublished data from 
Hoffman Lab). It has been reported that PDE7A antisense oligonucleotide inhibits cell 
proliferation and IL-2 production in both Hut78 T cell line and primary CD4+ T 
lymphocytes [25]. Thus, PDE7 was our original hypothesized in vivo target of BC12 in 
Jurkat cells. 
 The Hoffman Lab obtained a series of BC12 derivatives that have strong 
structural similarity to BC12 to study their preliminary structure-activity relationship on 
PDE7A and 7B (Figure 7). 5-FOA growth assays were performed on S. pombe strains 
expressing human PDE7A or PDE7B enzyme to assess PDE inhibitory capacity of these 
compounds (Figure 7B and 7C). Compounds with the ability to stimulate 5-FOA resistant 
growth demonstrate PDE7A or 7B inhibitory activity. BC12 displayed the strongest 
activity among 7 compounds in both assays (Figure 7B and 7C). BC12-4, which lacks the 
dimethylamino group at R1 position on A-ring (Figure 7A), is inactive in both assays, 
demonstrating that this functional group is essential for the PDE7A and 7B inhibitory 
activity of these compounds. In addition, we also observed that with different substitution 
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patterns on B-ring (Figure 7A), BC12-1, BC12-2, BC12-5, BC12-6, and BC12-7 are 
significantly less potent than the parent compound BC12 in both assays, indicating that 
substitutions on B-ring might not be well tolerated. In vitro PDE assays were also 
performed on the PDE7A catalytic domain (data not shown). BC12 showed the strongest 
inhibitory capacity among 7 structural analogs with IC50 of 0.77 µM. BC12-6 showed 
similar level of PDE7A inhibitory activity as that of BC12, while BC12-4 did not exhibit 
measureable PDE7A inhibitory activity when tested at 2 µM (unpublished data from 
Hoffman Lab).  
 BC12 and its derivative compounds were then tested for their effects on IL-2 
production in activated Jurkat cells (Figure 8A). Among 6 derivative compounds tested, 
BC12-4, BC12-5, and BC12-7 exhibited similar inhibitory effects on IL-2 production 
when compared to BC12; BC12-6 showed a minimal effect (Figure 8A). Parallel Jurkat 
cells were also analyzed for viability (Figure 8B). Many compounds decreased the 
number of viable cells (BC12-2, BC12-4, BC12-5 and BC12-7). All the others did not 
reduce the percentage of viable cells to lower than 70% (Figure 8B). 
 To uncover the correlation between in vitro PDE inhibitory activity and IL-2 
inhibitory effect, we sought to compare the effects of several key compounds. BC54 is 
the most potent PDE4 and PDE7 dual inhibitor identified by the Hoffman Lab (personal 
communication with Dr. Charles Hoffman). BC12 and BC12-6 are the two strongest 
PDE7 inhibitors among the 7 analogs and BC12-4 has no PDE7 inhibitory activity 
(Figure 7B and 7C). We compared the effects of BC12, BC12-4, BC12-6 and BC54 on 
IL-2 secretion in activated Jurkat cells (Figure 9). BC12-4 abolished IL-2 secretion, while 
BC12-6 and BC54 inhibited IL-2 secretion to about 70%, all at the dose of 10 µM (Figure 
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9). These results suggest that the inhibitory effects on IL-2 production by BC12 and 
BC12-4 do not rely on PDE7 inhibitory capacity. Thus, the in vivo target of BC12 that 
leads to IL-2 inhibition is not PDE7. 
   
BC12 augments activation signal towards the AP-1 signaling pathway in T cells 
 To understand the inhibitory mechanism of BC12 on IL-2 production, we sought 
to evaluate the activation status of signaling proteins that respond to TCR and CD28 
activation and lead to IL-2 gene transcription. Whole cell extracts were prepared and 
immunoblotted with antibodies against several signaling proteins. Phosphorylation of 
signaling proteins was induced by PHA/PMA stimulation for as early as 20 minutes 
(Figure 10). Phosphorylated Akt was already present in unstimulated cells, which is 
likely due to deficiency of PTEN in Jurkat cells [174]. Surprisingly, phosphorylation of 
several signaling proteins was augmented by BC12 treatment in addition to PHA/PMA 
stimulation, including ERK1/2, MEK1/2, RSK and JNK1/2, all of which are known 
components of the AP-1 signaling pathway (Figure 10), while the total protein level of 
ERK2 was not increased by BC12. Of note, BC12 alone did not induce phosphorylation 
of ERK1/2 or MEK1/2, indicating that BC12 amplifies the activation signal by 
PHA/PMA but does not initiate it. Although these results do not explain the inhibitory 
effect of BC12 on IL-2 production, it suggests a possible feedback mechanism that the 
inhibition of downstream IL-2 transcription may result in the hyper-activation of 
upstream AP-1 signaling pathway. 
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BC12 inhibits IL-2 expression through NFAT and NFκB mediated transcription 
 To investigate the mechanism of inhibition of BC12 on IL-2 production, we 
performed microarray analysis of the whole genome expression profile of stimulated 
Jurkat cells in the presence or absence of BC12. The analysis revealed that 378 genes 
were found affected by BC12 on PHA/PMA stimulated cells. While most of the genes 
were inhibited by BC12, including several cytokines and major transcription factors, 
some were increased in expression levels. Bioinformatic analysis of the microarray data 
indicated that several pathways were affected by BC12, among which NFκB pathway is 
related to IL-2 regulation. Interestingly, the expressions of transcription factors c-Fos and 
c-Jun were increased after BC12 treatment in the presence of stimuli. These results are 
consistent with our finding that BC12 significantly augments activation of AP-1 signaling 
pathway by stimuli (Figure 10), which regulates the transcription of both c-Fos and c-Jun 
[83].  
 To understand which of these pathways targeted by BC12 may result in inhibition 
of IL-2 expression, we analyzed the fold change of target gene expression of five groups 
of transcription factors: NFATc1/NFATc2, NFκB (p50/p65), c-Fos/FosB, c-Jun/JunB 
and Oct-1. Of the five major transcription factors known to regulate IL-2 gene 
expression, we found that genes regulated by NFκB were most affected by BC12, 
followed by NFAT regulated genes (Figure 11). Besides IL-2 gene, several target genes 
of NFκB had reduced levels of expression, such as IL-2Rα, TNFα and TNFβ. These 
results suggest that the NFκB pathway, and perhaps NFAT as well, are likely to be 
inhibited by BC12.  
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 With these results in mind, we sought to examine the protein levels of IκB, which 
is a key component in the NFκB pathway. In unstimulated T cells, NFκB dimers are 
sequestered by IκB proteins in cytoplasm. Stimulation induced nuclear translocation of 
NFκB requires liberation from IκB, which depends on inducible ubiquitination and 
degradation of IκB [86]. Whole cell extracts were prepared and immunoblotted with anti-
IκBα antibody. The protein levels of IκBα decreased in a transient manner when 
stimulated by PHA/PMA for 20 minutes in comparison to media control; IκBα levels 
recovered by 90 minutes (Figure 12, IκBα). In contrast to the rapid and transient turnover 
in stimulated Jurkat cells, BC12 inhibited the degradation of IκBα at 20 and 45 minutes 
and prevented its recovery at 90 minutes (Figure 12, IκBα). We also evaluated the 
activation status of IKKα/β, the catalytic dimer that phosphorylates IκB and targets its 
degradation (Figure 12, p-IKKα/β). The phosphorylation level of IKKα/β was not 
affected by BC12 at the time points examined. However, the phosphorylation level of 
IκBα was reduced at 45 and 90 minutes by BC12, even when the total IκBα level was 
higher in BC12 treated cells (Figure 12, p-IκBα). These results indicate that 
IκBα degradation is inhibited by BC12, at least partially due to reduced phosphorylation 
of IκBα. However, upstream kinases IKKα/β that phosphorylate IκB appear to be 
unaffected by BC12. Other components in the complex such as the regulatory subunit 
IKKγ may contribute to this effect. Taken together, BC12 inhibits IκB turnover, which is 
the likely mechanism that inhibit IL-2 expression. 
 We next examined nuclear translocation of NFκB family transcription factors. 
Nuclear extracts were prepared and immunoblotted with antibodies against each 
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individual NFκB family member. Activated NFκB is typically composed of RelA-
NFκB1 or c-Rel- NFκB1, the former contributes to early time points and the latter 
contributes to later [97]. Notably, RelA (p65), NFκB1 (p50), and c-Rel all showed 
decreased nuclear translocation in the presence of BC12 (Figure 13A). Specifically, 
NFκB1 was reduced to approximately 50% at all three time-points examined. RelA was 
decreased to 35% at 2 hours post BC12 treatment. Nuclear protein level of c-Rel was 
induced by stimulation at 3 hours and inhibited to 50% by BC12 (Figure 13A). Of note, 
nucleolin is located mainly in nucleolus and β-actin is a cytoplasmic protein. Antibodies 
against these two proteins were used to confirm the separation of nuclear and cytoplasmic 
fractions (Figure 13B) [12, 13]. Taken together, BC12 inhibits IκB turnover, leading to 
impaired nuclear translocation of NFκB family proteins, which is the likely mechanism 
of IL-2 inhibition. 
 In addition to NFκB family, nuclear translocation of other key transcription 
factors was also evaluated. NFATc2 is the major contributor in NFAT family that 
regulates the early stage of IL-2 transcription [78]. NFATc2 was detected in isolated 
nuclei of unstimulated Jurkat cells, consistent with other reports [13, 14]. The protein 
level of NFATc2 in the nucleus was not significantly changed after BC12 treatment 
(Figure 14). c-Fos and c-Jun were translocated to the nucleus after stimulation. The 
nuclear protein levels of c-Fos and c-Jun were not significantly decreased by BC12 
treatment (Figure 14). The nuclear protein level of CREB was not induced by stimulation 
or affected by BC12.  
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 To ensure the inhibitory effect on IL-2 production we observed was not restricted 
to PHA/PMA stimulation, Jurkat cells were stimulated with 20 ng/ml PMA and 1 µM 
Ionomycin in the absence or presence of 10 µM of BC12. Ionomycin is a calcium 
ionophore that is able to raise intracellular level of calcium, which results in activation of 
NFAT pathway. Ionomycin in combination of PMA can stimulate T cells and induce IL-2 
production [179]. Similar levels of inhibition on IL-2 production by BC12 and BC12-4 
were observed in ELISA (data not shown). We then sought to examine the ability of 
transcription factors to bind to the promoter region of IL-2 gene. Nuclear extracts were 
prepared and an electrophoresis mobility shift assay (EMSA) was performed. The 
radiolabeled NFκB-consensus-binding oligonucleotides were bound and shifted by 
nuclear proteins extracted from Jurkat cells stimulated for 2, 4, and 6 hours, but not 
control unstimulated Jurkat cells (Figure 15A). Stimulation in the presence of BC12 
reduced the amount of bound and shifted DNA probes (Figure 15A). Specificity of the 
binding was verified by adding increasing amount of the same unlabeled oligonucleotides 
as cold competitors, which completely competed off the binding of radiolabeled probes 
when present at 10 fold or more excess (Figure 15B). To examine the binding ability of 
nuclear NFAT protein to specific DNA regions, two different DNA probes were used, 
one corresponding to the distal NFAT site of the human IL-2 promoter (Figure 16A), and 
the other corresponding to NFAT-consensus-binding motif (Figure 16C). Nuclear extract 
binding to both probes were increased from 2 hours to 6 hours of stimulation, and 
inhibited by BC12 (Figure 16A and 16C). Specificity of the binding was also confirmed 
by competition experiments with inclusion of excess of cold probes (Figure 16B and 
16D). In addition, antibody super-shift assay was also performed with anti-NFATc2 and 
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anti-NFATc1 antibodies using nuclear extracts from 4 hour-stimulated cells (Figure 16B). 
Anti-NFATc2 antibody reduced the density of the specific band, which indicates 
prevention of the binding. Anti-NFATc1 antibody super-shifted the specific band, which 
indicates the formation of an antibody-NFAT-DNA probe complex (Figure 16B).  These 
results suggest that both NFATc1 and NFATc2 are present in nucleus and able to bind to 
the promoter region after 4 hours of stimulation.  
 In order to confirm the results we observed in EMSA correlate with the IL-2 
inhibitory effect by BC12, analogs BC12-4 and BC12-6 were also used to treat Jurkat 
cells in addition to PMA/Ionomycin stimulation for 4 hours. BC12-4 and BC12 inhibited 
the inducible binding of NFκB and NFAT to their specific consensus binding sites, while 
BC12-6 did not (Figure 17A and 17B). Interestingly, BC12 significantly increased the 
binding of AP-1 to its specific binding probe (Figure 17C), which is consistent with our 
findings that BC12 considerably augments activation of pathways upstream of AP-1 
(Figure 10). The binding of Oct-1 to its specific probe is not induced by stimulation or 
inhibited by any of the three compounds (Figure 17D). Taken together, BC12 and BC12-
4 inhibit NFκB and NFAT binding to their specific DNA probes, while not inhibiting the 
binding of AP-1 or Oct-1. BC12-6 does not show inhibitory effects on any transcription 
factors tested binding to their DNA probes. These results agree with our findings that 
both BC12 and BC12-4, but not BC12-6 inhibit IL-2 production in activated Jurkat cells, 
and suggest that inhibition of IL-2 production is through repressing NFκB and NFAT 
mediated transcription. 
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BC12 inhibits mouse primary T cell activation and proliferation 
 To understand whether the results in Jurkat cells are recapitulated in primary T 
cells, we moved on to investigate the role of BC12 in the activation and proliferation of 
mouse primary T cells. Mouse primary T cells express and secrete IL-2 in response to 
TCR engagement and subsequently require IL-2 for proliferation and survival. Total 
primary T cells were obtained from wild-type BALB/c mouse spleens. Activation of 
mouse primary T cells was achieved by stimulation with PMA and Ionomycin (Ion). 
Compounds BC12, BC12-4 and BC12-6 were evaluated in mouse primary T cells as well 
as the solvent control, DMSO (Figure 18). The combination of PMA/Ionomycin 
stimulated IL-2 secretion at all three time-points (Figure 18, PMA/Ion/DMSO). BC12-6 
did not exhibit significant inhibition at 8 hours, but reduced the level of secreted IL-2 to 
approximately 80% at 24 hours and 48 hours (Figure 18, PMA/Ion/BC12-6). In the 
presence of BC12, IL-2 secretion was reduced to about 20% at all three time-points 
(Figure 18, PMA/Ion/BC12), which was less potent compared to the effect on Jurkat cells 
(inhibited to 2%) (refer to Figure 8A and 9). BC12-4, however, abolished IL-2 secretion 
to a level that was undetectable by the method (Figure 18, PMA/Ion/BC12-4). Overall, 
BC12 and its two derivatives showed similar effects on IL-2 secretion in stimulated 
mouse primary T cells as in Jurkat cells, which suggests a possibly similar off-target 
mechanism. 
 We then evaluated the effect of BC12 and its derivatives on mouse primary T cell 
viability (Figure 19). In addition to PMA/Ionomycin stimulation, BC12 and BC12-4 did 
not decrease cell viability at the dose of 10 µM. BC12-6 slightly increased cell viability 
in addition to stimulation. In the absence of PMA/Ionomycin, mouse primary T cells 
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remained above 90% viable after 24 hour-treatment with BC12 (Figure 19). These results 
confirmed that the inhibitory effect on IL-2 production was not attributable to cell death. 
 Because IL-2 is required for primary T cells to proliferate, we next evaluated the 
effect of BC12 on mouse primary T cell proliferation induced by PMA/Ionomycin. We 
analyzed cell cycle entry and progression in mouse T cells by propidium iodide staining 
and flow cytometry. Mouse primary T cells did not enter the cell cycle or proliferate 
without stimulation (Figure 20A, Media). Approximately 30% of cells entering S+G2/M-
phase of cell cycle after treating cells with PMA/Ionomycin for 48 hours (Figure 20A and 
20B, PMA/Ion 48hrs). DMSO or BC12-6 treated cells exhibit minimal effect on the 
percentage of S+G2/M-phase cells in comparison to PMA/Ionomycin stimulated cells 
(Figure 20A, PMA/Ion+DMSO and PMA/Ion+BC12-6). In contrast, treatment of 
stimulated T cells with BC12 or BC12-4 resulted in inhibition of cell cycle entry (Figure 
20A and 20B), as the percentage of S+G2/M-phase cells were decreased to the basal level 
compared to untreated cells.  These results agree with the effect of BC12 and its 
derivatives on IL-2 secretion in activated mouse primary T cells (Figure 18) and indicate 
that the inhibition of cell cycle entry by BC12 and BC12-4 is a result of inhibited IL-2 
production. To note, hypodiploid DNA indicates cells undergoing apoptosis. Stimulated 
mouse primary T cells treated with BC12-6 did not increase the percentage of 
hypodiploid DNA. Treating cells with BC12 resulted in approximately 10% increase in 
the percentage of hypodiploid DNA at 24 hours and 20% increase at 48 hours (Figure 21). 
The inhibition of IL-2 production and cell cycle entry in mouse primary T cells may lead 
to apoptosis.  
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 We then evaluated signaling pathways in activated mouse primary T cells in the 
presence of BC12. Whole cell extracts were prepared and immunoblotted for signaling 
proteins that lead to IL-2 expression. Similar to Jurkat cells, phosphorylation levels of 
ERK1/2 and RSK were increased by BC12 in stimulated mouse primary T cells, while 
BC12 alone did not induce phosphorylation of any proteins tested (Figure 22).  
 Taken together, BC12 and BC12-4 inhibit IL-2 production in mouse primary T 
cells without measurably affecting cell viability within 24 hours, leading to prevention of 
cell cycle entry and apoptosis after prolonged treatment. Similar to Jurkat cells, hyper-
activation of some signaling proteins by BC12 was observed in mouse primary T cells.  
 
BC12 inhibits IL-2 transcription in activated human primary T cells 
 After investigating the impact of BC12 on human Jurkat cells and mouse primary 
T cell activation, we sought to evaluate its efficacy in human primary T cells. Human 
primary T cells were obtained from healthy donors' blood. We first sought to examine IL-
2 secretion from stimulated human primary T cells in the presence of BC12 by ELISA. 
IL-2 secretion was induced when T cells were stimulated with PMA and Ionomycin 
(Figure 23A), or with physiological ligands anti-CD3 and anti-CD28 antibodies (Figure 
23B) for 24 hours and 48 hours. The presence of BC12 inhibited IL-2 secretion in 
stimulated human primary T cells at both 24 and 48 hours (Figure 23A and B).  
 We then examined the effect of BC12 on human primary T cell viability. BC12, at 
a dose of 10 µM, reduced the percentage of viable cells from about 72% of PMA and 
Ionomycin stimulated cells to 58% (Figure 24A), which indicates that the complete 
inhibition of IL-2 secretion by BC12 cannot be attributed to cell death. We also evaluated 
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the effect of BC12 on cell viability in the absence of stimuli. BC12 at 10 µM increased 
the percentage of cell death from 16% to 37%, averaging data from both 24 and 48 hours 
of treatment (Figure 24B). Increasing dose of BC12 resulted in increased cell death, with 
a maximum of 75% cell death when treated at a dose of 50 µM or higher (Figure 24B).   
 We also examined the effects of derivatives BC12-4 and BC12-6 on activated 
human primary T cells (Figure 25). Similarly to Jurkat cells (Figure 9) and mouse 
primary T cells (Figure 18), BC12-4 inhibited IL-2 secretion while BC12-6 did not, 
indicating a probably similar inhibition mechanism of these compounds on T cells from 
different origins.  
  Next, we sought to determine the mRNA level of IL-2 gene in activated human 
primary T cells in the presence or absence of BC12. After stimulation with 
PMA/Ionomycin for 4 hours, IL-2 mRNA level was increased by about 22000 fold. In the 
presence of 10 µM of BC12 in addition to stimuli, IL-2 mRNA level was induced to 
about 2200 fold compared to untreated human T cells, which was 90% reduction 
compared to PMA/Ionomycin stimulated cells (Figure 26). This result suggests that BC12 
inhibits IL-2 gene transcription in activated human primary T cells similarly as in Jurkat 
cells. Taken together, BC12 and its derivatives exhibit similar effects on IL-2 production 
in activated human primary T cells as in Jurkat cells and mouse primary T cells, 
indicating the same off-target inhibitory mechanism. IL-2 production is inhibited at 
mRNA level, and the inhibitory effect is not a result of loss of cells from cell death.  
 Finally, we sought to investigate the effect of BC12 on other cytokine secretion 
from activated human CD4+ T cells. Eleven cytokines were tested, including three Th1 
specific, four Th2 specific and four Th17 specific cytokines (Figure 27 and Table 1). 
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Among the eleven cytokines, TGFβ1 exhibited a high level of secretion in untreated cells, 
and nine cytokines were induced to a detectable level after PMA/Ionomycin stimulation 
for 24 hours, with the exception of IL-12 and G-CSF (Table 1). Interestingly, in the 
presence of 10 µM of BC12, secretion levels of six cytokines were significantly 
decreased, including all four Th2 specific cytokines, IL-4, IL-5, IL-10, and IL-13, but no 
Th1 specific cytokines (Figure 27 and Table 1). Secretion of three cytokines were not 
affected or mildly inhibited, including two Th1 specific cytokines, IFNγ and 
TNFα (Figure 27 and Table 1). These data indicate that BC12 selectively inhibits Th2 
specific cytokines over Th1 cytokines, suggesting a possible Th1 polarization effect of 
BC12 on human primary CD4+ T cells.  
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FIGURES AND LEGENDS 
 
 
Figure 1. BC12 inhibits IL-2 secretion in activated Jurkat cells in a dose-dependent 
manner. Jurkat cells were cultured in media alone, treated with DMSO, or stimulated by 
the combination of 0.5 µg/ml PHA and 50 ng/ml PMA. Stimulated Jurkat cells were 
simultaneously treated with increasing dose of BC12 (1 µM, 5 µM and 10 µM) or DMSO 
for 24 hours. Supernatants were collected and analyzed by ELISA as described in 
Material and Methods to examine the concentration of IL-2 secreted. The data are 
representative of two independent experiments, each conducted in duplicates. Error bars 
reflect standard deviation from the mean of duplicate measurements. 
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Figure 1.  
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Figure 2. BC12 does not severely reduce cell viability. Jurkat cells were cultured in 
media alone or treated with 10 µM of BC12 with increasing doses along with 0.5 µg/ml 
PHA and 50 ng/ml PMA stimulation for 24 hours. The viability of cells was determined 
by propidium iodide staining. Samples were analyzed by flow cytometry as described in 
Material and Methods. The data are represented as the percentage of Jurkat cells that are 
negative for propidium iodide staining. The data are representative of 10,000 cells and 
two independent experiments.  
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Figure 2 
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Figure 3. Time course of IL-2 inhibition by BC12. Jurkat cells were stimulated with a 
combination of 0.5 µg/ml PHA and 50 ng/ml PMA, or treated with 10 µM of BC12 
simultaneously with stimulation up to 24 hours. Supernatant samples were taken at 
indicated time points and were analyzed by ELISA as described in Material and Methods 
to examine the concentration of IL-2 secreted. The data are representative of two 
independent experiments, each conducted in duplicates. Error bars reflect standard 
deviation from the mean of duplicate measurements. 
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Figure 3 
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Figure 4. BC12 inhibits endogenous IL-2 protein production. A, Jurkat cells were 
cultured in media alone, treated with DMSO, 0.5 µg/ml PHA and 50 ng/ml PMA or PHA 
and PMA plus 10 µM of BC12, all in the presence of monensin, a Golgi inhibitor to 
block IL-2 secretion. Whole cell extracts were prepared from Jurkat cells treated for 12 
hours, and Western blotting was performed with an anti-human IL-2 antibody. The blot 
was stripped and reprobed with an anti-β-actin antibody to ensure equal loading. 
Quantification of the Western blotting bands was obtained with ImageJ software (v1.45s). 
Band densities are listed as fold increase above first detected band relative to β-actin 
loading control. The data are representative of two independent experiments. B, Jurkat 
cells were cultured in media alone, treated with 0.5 µg/ml PHA and 50 ng/ml PMA in the 
presence or absence of monensin for 24 hours. Supernatant samples were taken and 
analyzed by ELISA as described in Material and Methods. The data are representative of 
two independent experiments, each conducted in duplicates. Error bars reflect standard 
deviation from the mean of duplicate measurements. 
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Figure 4 
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Figure 5. BC12 decreases IL-2 mRNA level in activated Jurkat cells. Jurkat cells were 
stimulated with 0.5 µg/ml PHA and 50 ng/ml PMA in the presence or absence of 10 µM 
of BC12. RNA was extracted at the indicated times as described in Material and 
Methods. IL-2 mRNA was analyzed by semi-quantitative reverse transcription-PCR 
following normalization to β-actin as described in Material and Methods. The data are 
average from two independent experiments and error bars reflect standard deviation from 
the mean of two independent experiments. 
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 Figure 5 
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Figure 6. BC12 does not affect IL-2 mRNA stability. Jurkat cells were previously 
stimulated with 0.5 µg/ml PHA and 50 ng/ml PMA for 4 hours. DMSO or 10 µM BC12 
or 1 µg/ml Cyclosporin A (CsA) or CsA+BC12 were then added. Levels of mRNA are 
shown as a percentage of IL-2 mRNA after the initial stimulation. The fold induction of 
IL-2 mRNA after the initial 4 hours of stimulation was 1054 compared to unstimulated 
cells. The data are representative of three independent experiments and error bars reflect 
standard deviation from the mean of three independent experiments. 
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Figure 6 
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Figure 7. BC12 and its derivatives have different PDE7A and 7B inhibitory activity. 
A, Structures of BC12 and its derivative compounds. B, BC12 and its derivative 
compounds BC12-1, BC12-2, BC12-4, BC12-5, BC12-6 and BC12-7 were used to treat a 
human-PDE7A-expressing strain with increasing doses (0, 0.21, 0.31, 0.46, 0.69, 1.03, 
1.54, 2.31, 3.47, 5.20, 7.81, 11.71 and 17.6 µM). C, BC12 and its derivative compounds 
BC12-1, BC12-2, BC12-4, BC12-5, BC12-6 and BC12-7 were used to treat a human-
PDE7B-expressing strain with increasing doses (0, 0.21, 0.31, 0.46, 0.69, 1.03, 1.54, 
2.31, 3.47, 5.20, 7.81, 11.71, 17.6, 26.4, 39.5, 59.3 and 88.9 µM). Optical densities 
(OD600) of the cultures were determined after 48 hours incubation at 30 oC, using a 
microplate reader to measure growth. Each value represents the average reading of four 
wells. These assays were conducted by Dr. Arlene Wyman.   
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Figure 7 
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B                                         Inhibition of PDE7A by BC12 series 
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Figure 8. BC12 and its derivatives have various effects on IL-2 secretion. Jurkat cells 
were cultured in media alone, or treated with DMSO, or stimulated with 0.5 µg/ml PHA 
and 50 ng/ml PMA in the presence of DMSO, 10 µM of BC12 (indicated as 12) or 
compounds of similar structure with that of BC12 (indicated as 12-1 to 12-7) for 15 
hours. A, Supernatant samples were collected and analyzed by ELISA as described in 
Material and Methods. The data are representative of two independent experiments, each 
conducted in duplicates. Error bars reflect standard deviation from the mean of duplicate 
measurements. B, The viability of cells was determined by propidium iodide staining. 
Samples were analyzed by flow cytometry as described in Material and Methods. The 
data are represented as the percentage of Jurkat cells that are negative for propidium 
iodide staining. The data are representative of 10,000 cells and two independent 
experiments. 
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Figure 9. BC12 inhibits IL-2 expression not through PDE7. Jurkat cells were cultured 
in media alone, or treated with DMSO, or stimulated with 0.5 µg/ml PHA and 50 ng/ml 
PMA in the presence of DMSO, 10 µM of BC12, BC12-4, BC12-6 or BC54 for 15 hours. 
Supernatant samples were collected and analyzed by ELISA as described in Material and 
Methods. The data are representative of two independent experiments, each conducted in 
duplicates. Error bars reflect standard deviation from the mean of duplicate 
measurements. 
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Figure 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!100$
0$
100$
200$
300$
400$
500$
Me
dia
$
DM
SO
$
PH
A/
PM
A/
DM
SO
$
PH
A/
PM
A/
BC
12
$
PH
A/
PM
A/
BC
12
!4$
PH
A/
PM
A/
BC
12
!6$
PH
A/
PM
A/
BC
54
$
IL
!2
$S
ec
re
<o
n$
(p
g/
m
l)
	  	   81	  
Figure 10. BC12 augments activation signal towards AP-1 pathway. Jurkat cells were 
cultured in media, treated with DMSO, stimulated with a combination of PHA/PMA, or 
pre-treated with 10 µM of BC12 for 20 minutes before incubating with BC12 plus 
PHA/PMA or DMSO for various lengths of time. Whole cell extracts were prepared and 
Western blotting was performed with antibodies against various signaling proteins as 
described in Material and Methods. The blot was stripped and reprobed for anti-HSP90 
antibody to ensure equal loading of each sample. Quantification of the Western blotting 
bands was obtained with ImageJ software (v1.45s). Both top and bottom band densities 
are listed as fold increase above first detected band. The data are representative of three 
independent experiments.  
 
 
 
 
 
 
 
 
 
  
	  	   82	  
Figure 10 
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Figure 11. Microarray analysis of IL-2 gene regulators suggests NFκB the most 
likely transcription factor responsible for down-regulation of IL-2 gene. Jurkat cells 
were treated with media, stimulated with 0.5 µg/ml PHA and 50ng/ml PMA in the 
presence or absence of 10 µM of BC12. Each treatment was prepared in quadruplicates. 
RNA was extracted after 3 hours of treatment as described in Material and Methods, and 
was tested by the Affymetrix facility at Boston University for whole genome expression 
profile. Microarray expression data were analyzed based on IL-2 gene regulators. Five 
groups of transcription factors were analyzed: NFATc1/NFATc2, NFκB (p50/p65), c-
Fos/FosB, c-Jun/JunB and Oct-1, as candidates responsible for down-regulation of the IL-
2 gene. Target genes of these transcription factors were obtained from TRANSFAC 
database and their expression levels were analyzed. The fold changes of target gene 
expression for five groups of transcription factors were illustrated on a color scale. The 
value was calculated by (stimuli with BC12 treatment - stimuli treatment)/ untreated 
control. White color represents that the gene is not a target of the transcription factors at 
corresponding column. Blue color indicates the gene expression is reduced, whereas 
orange color indicates the gene expression is increased when treated with BC12. This 
analysis was conducted by Dr. Lu Zhang.  
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Figure 11 
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Figure 12. BC12 inhibits IκBα  turnover at early time points. Jurkat cells were 
cultured in media, stimulated with 0.5 µg/ml PHA and 50ng/ml PMA, or pre-treated 
with10 µM of BC12 for 20 minutes before incubating with PHA/PMA plus BC12 for 
various lengths of time. Whole cell extracts were prepared and Western blotting was 
performed with anti-IκBα, p-IκBα, or p-IKKα/β antibody as described in Material and 
Methods. The blot was stripped and reprobed for anti-HSP90 antibody to ensure equal 
loading of each sample. Quantification of the Western blotting bands was obtained with 
ImageJ software (v1.45s). Band densities are listed as fold increase above first detected. 
The data are representative of two independent experiments. 
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Figure 12 
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Figure 13. BC12 inhibits nuclear translocation of some NFκB family proteins. A, 
Jurkat cells were cultured in media, stimulated with 0.5 µg/ml PHA and 50ng/ml PMA, 
or pre-treated with 10 µM of BC12 for 20 minutes before incubating with PHA/PMA 
plus BC12 for various lengths of time. Nuclear extracts were prepared and Western 
blotting was performed with anti-NFκB1, anti-RelA or anti-c-Rel antibody as described 
in Material and Methods. The blot was stripped and reprobed for anti-nucleolin to verify 
equal loading of each nuclear extract sample. Quantification of the Western blotting 
bands was obtained with ImageJ software (v1.45s). Band densities are listed as fold 
increase above first detected band relative to nucleolin loading control. The data are 
representative of two independent experiments. B, The nuclear and cytosolic extracts 
were prepared from Jurkat cells stimulated with PHA/PMA for 2 hours. Anti-nucleolin or 
anti-β-actin antibodies were used to verify complete separation of nuclear and cytosolic 
proteins. 
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Figure 13 
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Figure 14. BC12 does not affect nuclear translocation of NFAT, AP-1 or CREB. A, 
Jurkat cells were cultured in media, stimulated with 0.5 µg/ml PHA and 50ng/ml PMA, 
or pre-treated with 10 µM of BC12 for 20 minutes before incubating with PHA/PMA 
plus BC12 for various lengths of time. Nuclear extracts and cytosolic extracts were 
prepared and Western blotting was performed with anti-NFATc2, anti-c-Fos or anti-c-Jun 
antibody as described in Material and Methods. The blot was stripped and reprobed for 
anti-nucleolin to verify equal loading of each nuclear extract sample. Quantification of 
the Western blotting bands was obtained with ImageJ software (v1.45s). Band densities 
are listed as fold increase above first detected band. The data are representative of two 
independent experiments. B, The nuclear and cytosolic extracts were prepared from 
Jurkat cells stimulated with PHA/PMA for 2 hours. Anti-nucleolin or anti-β-actin 
antibodies were used to verify complete separation of nuclear and cytosolic proteins. 
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Figure 15. BC12 inhibits the binding of NFκB to the consensus NFκB-binding probe. 
A, Jurkat cells were cultured in media alone, or stimulated with 20 ng/ml PMA and 1 µM 
Ionomycin in the absence or presence of 10 µM of BC12. Nuclear extracts of Jurkat cells 
were prepared at indicated times and analyzed by EMSA using radiolabeled probes 
corresponding to the NFκB-consensus-binding site as described in Material and 
Methods. B, Jurkat cells were cultured in media alone, or stimulated with 20 ng/ml PMA 
and 1 µM Ionomycin for 4hours. Nuclear extracts of Jurkat cells were prepared and 
analyzed by EMSA using radiolabeled probes corresponding to the NFκB-consensus-
binding site as described in Material and Methods. Competition experiments were 
performed by adding 1, 10, or 25 fold molar excess of the same unlabelled NFκB-
consensus-binding oligonucleotide to the reaction mixtures as indicated in the figure. The 
specific shifted bands are indicated by red arrows. Quantification of the specific bands 
was obtained with ImageJ software (v1.45s). Band densities are listed as fold increase 
above first detected band. The data are representative of two independent experiments. 
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Figure 16. BC12 inhibits the binding of NFAT to the NFAT-binding probes. A, 
Jurkat cells were cultured in media alone, or stimulated with 20 ng/ml PMA and 1 µM 
Ionomycin in the absence or presence of 10 µM of BC12. Nuclear extracts of Jurkat cells 
were prepared at indicated times and analyzed by EMSA using radiolabeled probes 
corresponding to the distal NFAT site of the human IL-2 promoter as described in 
Material and Methods. B, Jurkat cells were cultured in media alone, or stimulated with 20 
ng/ml PMA and 1 µM Ionomycin for 4hours. Nuclear extracts of Jurkat cells were 
prepared and analyzed by EMSA using radiolabeled probes corresponding to the distal 
NFAT site of the human IL-2 promoter. Competition experiments were performed by 
adding 1, 10, or 25 fold molar excess of the same unlabelled NFAT-binding 
oligonucleotide to the reaction mixtures as indicated in the figure. Supershift assay was 
performed by adding 4 µg anti-NFATc1 or anti-NFATc2 antibodies to the reaction 
mixtures. C, Jurkat cells were cultured in media alone, or stimulated with 20 ng/ml PMA 
and 1 µM Ionomycin in the absence or presence of 10 µM of BC12. Nuclear extracts of 
Jurkat cells were prepared at indicated times and analyzed by EMSA using radiolabeled 
probes corresponding to the NFAT-consensus-binding site as described in Material and 
Methods. D, Jurkat cells were cultured in media alone, or stimulated with 20 ng/ml PMA 
and 1 µM Ionomycin for 4hours. Nuclear extracts of Jurkat cells were prepared and 
analyzed by EMSA using radiolabeled probes corresponding to the NFAT-consensus-
binding site. Competition experiments were performed by adding 1, 10, or 25 fold molar 
excess of the same unlabelled NFAT-consensus-binding oligonucleotide to the reaction 
mixtures as indicated in the figure. The specific shifted bands are indicated by red arrows. 
The super-shifted band is indicated by blue arrow. Quantification of the specific bands 
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was obtained with ImageJ software (v1.45s). Band densities are listed as fold increase 
above first detected band. The data are representative of two independent experiments. 
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Figure 16 
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Figure 17. BC12 and its analogs have different effects on Transcription factor 
binding activity. Jurkat cells were cultured in media alone, or stimulated with 20 ng/ml 
PMA and 1 µM Ionomycin in the absence or presence of 10 µM of indicated compound 
for 4 hours. Nuclear extracts of Jurkat cells were prepared as described in Material and 
Methods. A, Nuclear extracts were analyzed by EMSA using radiolabeled probes 
corresponding to the NFκB-consensus-binding site as described in Material and 
Methods. B, Nuclear extracts were analyzed by EMSA using radiolabeled probes 
corresponding to the distal NFAT site of the human IL-2 promoter. C, Nuclear extracts 
were analyzed by EMSA using radiolabeled probes corresponding to the AP-1-
consensus-binding site. D, Nuclear extracts were analyzed by EMSA using radiolabeled 
probes corresponding to the Oct-1-consensus-binding site. The specific shifted bands are 
indicated by red arrows. Quantification of the specific bands was obtained with ImageJ 
software (v1.45s). Band densities are listed as fold increase above first detected band. 
The data are representative of two independent experiments. 
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Figure 17 
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Figure 18. BC12 and BC12-4 inhibit IL-2 secretion in activated mouse primary T 
cells. Mouse primary T cells were isolated from mouse spleens and cultured in media 
alone, or stimulated with 20 ng/ml PMA and 1 µM Ionomycin in the presence of DMSO 
or 10 µM of indicated compound. Supernatant from media sample served as time point 0. 
Supernatant from other samples were taken at 8, 24, and 48 hours. All supernatant 
samples were analyzed by ELISA to examine mouse IL-2 concentration as described in 
Material and Methods. The data are representative of two independent experiments, each 
conducted in duplicates. Error bars reflect standard deviation from the mean of duplicate 
measurements. 
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Figure 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!100$
0$
100$
200$
300$
400$
500$
600$
700$
PMA/Ion/DMSO$ PMA/Ion/BC12$ PMA/Ion/BC12!4$ PMA/Ion/BC12!6$
M
ou
se
$IL
!2
$(p
g/
m
l)$
0$hrs$
8$hrs$
24$hrs$
48$hrs$
	  	   100	  
Figure 19. BC12, BC12-4 and BC12-6 do not significantly reduce mouse primary T 
cell viability. Mouse primary T cells were isolated from mouse spleens and cultured in 
media alone, or stimulated with 20 ng/ml PMA and 1 µM Ionomycin in the presence of 
DMSO or 10 µM of indicated compound, or in the presence 10 µM of BC12 for 24 
hours. The viability of cells was determined by propidium iodide staining. Samples were 
analyzed by flow cytometry as described in Material and Methods. The data are 
represented as the percentage of mouse primary T cells that are negative for propidium 
iodide staining. The data are representative of 10,000 cells and two independent 
experiments. 
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Figure 19 
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Figure 20. BC12 inhibits mouse primary T cell proliferation. Mouse primary T cells 
were isolated from mouse spleens and cultured in media alone, or with 20 ng/ml PMA 
and 1 µM Ionomycin in the absence or presence of DMSO or 10 µM of indicated 
compound. At the indicated times, mouse T cells were stained with propidium iodide and 
cell cycle analyzed by flow cytometry as described in Materials and Methods. A, The 
data are represented as the percentage of mouse T cells in the S+G2/M-phase of the cell 
cycle. The data are representative of 10,000 cells. B, Example flow cytometry data at 48 
hours with indicated treatments.  
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Figure 20 
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Figure 21. BC12 induces a moderate level of increase in hypodiploid DNA resulting 
in apoptosis in mouse primary T cells. Mouse primary T cells were isolated from 
mouse spleens and cultured in media alone, or with 20 ng/ml PMA and 1 µM Ionomycin 
in the absence or presence of DMSO or 10 µM of indicated compound. A, At the 
indicated times, mouse primary T cells were stained with propidium iodide and cell cycle 
analyzed by flow cytometry as described in Materials and Methods. The data are 
represented as the percentage of mouse T cells in the sub-G0/G1-phase of the cell cycle. 
The data are representative of 10,000 cells.  
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Figure 21 
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Figure 22. BC12 augments activation signals in activated mouse primary T cells. 
Mouse primary T cells were cultured in media, pre-treated with 10 µM of BC12 or 
DMSO for 20 minutes before stimulating with 20 ng/ml PMA and 1 µM Ionomycin for 
various lengths of time, or treated with 10 µM of BC12 for 45 minutes. Whole cell 
extracts were prepared and Western blotting was performed with anti-phospho-ERK, 
anti-phospho-RSK90 and anti-phospho-IKKα/β antibodies as described in Material and 
Methods. The blot was stripped and reprobed for anti-β-actin antibody to ensure equal 
loading of each sample. Quantification of the Western blotting bands was obtained with 
ImageJ software (v1.45s). Both top and bottom band densities are listed as fold increase 
above first detected band relative to β-actin loading control. The data are representative 
of two independent experiments. 
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Figure 22 
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Figure 23. BC12 inhibits IL-2 secretion in activated human primary T cells. Human 
primary T cells were isolated from donor’s blood as described in Material and Methods. 
A, Human primary T cells were stimulated with 20 ng/ml PMA and 1 µM Ionomycin in 
the presence or absence of 10 µM of BC12. The data are representative of two 
independent experiments, each conducted in duplicates. Error bars reflect standard 
deviation from the mean of duplicate measurements. B, Human primary T cells were 
stimulated with anti-CD3/anti-CD28 antibodies as described in Material and Methods, in 
the presence or absence of 10 µM of BC12. Supernatant samples were taken at indicated 
times and analyzed by ELISA to examine human IL-2 concentration as described in 
Material and Methods. The data are representative of two independent experiments, each 
conducted in duplicates. Error bars reflect standard deviation from the mean of duplicate 
measurements. 
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Figure 23 
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Figure 24. BC12 induces cell death in human primary T cells. A, Human primary T 
cells were isolated from donor's blood as described in Material and Methods. A, Cells 
were cultured in media alone, or stimulated with 20 ng/ml PMA and 1 µM Ionomycin in 
the presence or absence of 10 µM of BC12 for 24 hours.  Cell viability was determined 
by propidium iodide staining. Samples were analyzed by flow cytometry as described in 
Material and Methods. The data are represented as the percentage of cells that are 
negative for propidium iodide staining. B, Human primary T cells were cultured in media 
or treated with increasing doses of BC12 (0.05 µM, 0.5 µM, 2.5 µM, 5 µM, 10 µM, 25 
µM, 50 µM and 100 µM) for 24 hours or 48 hours. Cell viability was determined by 
propidium iodide staining. Samples were analyzed by flow cytometry as described in 
Material and Methods. The data are represented as the percentage of cells that are 
positive for propidium iodide staining. The data are representative of 10,000 cells. 
Titration of BC12 was repeated at doses 5 µM, 10 µM, 20 µM, 50 µM and 100 µM. The 
same trend was observed in two independent experiments. 
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Figure 24 
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Figure 25. BC12 and BC12-4, but not BC12-6, inhibit IL-2 secretion in activated 
human primary T cells. Human primary T cells were stimulated with anti-CD3/anti-
CD28 antibodies as described in Material and Methods, in the presence or absence of 10 
µM of BC12, BC12-4 or BC12-6 for 24 hours. Supernatant samples were collected and 
analyzed by ELISA to examine human IL-2 concentration as described in Material and 
Methods. The data are representative of two independent experiments, each conducted in 
duplicates. Error bars reflect standard deviation from the mean of duplicate 
measurements. 
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Figure 25 
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Figure 26. BC12 decreases the IL-2 mRNA level in activated human primary T cells. 
Human primary T cells were isolated from donor’s blood and stimulated with 20 ng/ml 
PMA and 1 µM Ionomycin in the presence or absence of 10 µM of BC12 for 4 hours. IL-
2 mRNA was analyzed by semi-quantitative RT-PCR following normalization to β-actin 
as described in Material and Methods. Error bars reflect standard deviation from the 
mean of triplicate measurements. 
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Figure 26 
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Figure 27. BC12 selectively inhibits Th2 cytokines over Th1. Human CD4+ T cells 
were cultured in media alone, or stimulated with 20 ng/ml PMA and 1 µM Ionomycin in 
the presence or absence of 10 µM of BC12. Supernatant samples were collected at 24 
hours and analyzed by multi-cytokine ELISA as described in Material and Methods. The 
same trend was observed in two independent experiments. 
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Figure 27 
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Table 1. BC12 selectively inhibits Th2 cytokines over Th1. Cytokines tested in Figure 
25 were sorted by cell types that secret them by color (Th1 as red, Th2 as blue, Th17 as 
yellow and Treg as purple), or by secretion response to BC12 into inhibited, not affected, 
and inconclusive.  
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Table 1.  
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Chapter Two 
 
BC12 induces apoptosis in LY18, U937 cells and primary B 
cells 
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RESULTS 
 
BC12 induces apoptosis in LY18 cells and human primary B cells 
 It has been reported that PDE4 inhibitors induce apoptosis in malignant lymphoid 
cells [6–10]. Theophylline and PDE4 inhibitors were reported to augment glucocorticoid-
mediated apoptotic effects in B cell chronic lymphocytic leukemia (B-CLL) [9].  Our 
collaborator, Dr. Hoffman and his laboratory at Boston College, also tested several novel 
in vitro PDE4 and PDE7 inhibitors on B-CLL cells. Some of these compounds exhibited 
potent activity in inducing apoptosis in B-CLL cells (unpublished data). LY18 is a human 
Diffuse Large B Cell Lymphoma (DLBCL) cell line [159], and my study sought to use 
LY18 cell line as a model system for malignant human B cells.  
 To begin to evaluate the effect of PDE inhibitors on human LY18 cells, we tested 
a series of in vitro PDE4 and PDE7 inhibitors identified from high-throughput fission-
yeast-based screen (HTS) by Hoffman Lab. Among the 5 compounds we tested, BC54 
was the most potent PDE4 and PDE7 dual inhibitor identified in both HTS and in vitro 
PDE assays, which also induced a higher percentage of apoptosis in B-CLL cells than a 
combination of rolipram and BRL50481 (unpublished data). BC12 is one of the best 
PDE7A inhibitors in both HTS and in vitro assays. BC38 is a moderate inhibitor of 
PDE7A and 7B in cell-based assays. BC51 is an in vitro PDE4A and 7A inhibitor. BC58 
is a potent in vitro inhibitor of both PDE4B and 4D (unpublished data). Surprisingly, the 
effects on LY18 cell viability were not correlated to the PDE inhibitory activity of the 
compounds (Figure 28). Specifically, BC12 exhibited the most significant effect on LY18 
cell viability after 48 hours of treatment, while the most potent and broad-spectrum 
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inhibitor BC54 did not display a measurable effect up to a dose of 100 µM compared to 
the DMSO control (Figure 28A). We then compared the effects of BC12, BC38 and 
rolipram at a dose of 20 µM; BC12 was the only compound that significantly decreased 
cell viability at this dose (Figure 28B). 
 To further confirm the effect of BC12 on LY18 cell viability, we performed a 
more detailed dose-titration of BC12 and analyzed cell viability at 24, 48 and 72 hours 
post treatment by propidium iodide staining followed by flow cytometric analysis. BC12 
induced LY18 cell death in a dose-dependent manner (Figure 29). At a dose of 20 µM, 
BC12 resulted in about 95% of cell death at 24 hours (Figure 29).  
 We next sought to determine whether LY18 cells were undergoing apoptosis after 
BC12 treatment. The presence of apoptotic cells was detected by TUNEL assay, which 
labels the terminal end of DNA to indicate DNA fragmentation. BC12 induced 
approximately 35% of apoptosis at 10 µM, and 75% at 20 µM at both 24 and 48 hours 
(Figure 30).  
 To obtain further evidence of the pathway underlying the apoptotic effect induced 
by BC12 on LY18 cells, we analyzed caspase pathway activation by Western blotting. 
Following treatment with 20 µM of BC12, LY18 cells displayed a time-dependent 
increase in active caspase 8 and caspase 3 levels (Figure 31A, BC12). Specifically, 
caspase 8 cleavage and activation was observed at 3 hours post treatment and peaked at 
12 hours. Full-length caspase 3 levels showed a decrease at 12 hours to about 60% and 
cleaved caspase 3 was observed at 24 hours (Figure 31A, BC12). Note that both 
antibodies detect full-length caspases and the large fragment of capases but not small 
ones. Due to the limited sensitivity of Western blotting, an alternative approach was also 
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employed. After treating with 20 µM of BC12 for indicated length of time, LY18 cells 
were stained for active caspase 3 and analyzed by flow cytometry. From 12 to 48 hours, 
approximately 90% of the cells were stained positive for active caspase 3 (Figure 31B). 
Of note, the flow cytometric analysis is more sensitive and quantitative insofar as it 
detects individual cells for the presence of cleaved and active caspase 3, while Western 
blotting analyzes the cell population as a whole. These results indicate that most of the 
cells activate caspase pathway by 12 hours post BC12 treatment and that in apoptotic 
LY18 cells, only a small portion of caspase 8 and caspase 3 protein are cleaved and 
activated, while the majority remain inactive pro-enzymes.  
 Active caspase 3 proteolytically cleaves and activates other targets relevant to 
apoptosis, including Poly ADP Ribose Polymerase (PARP) [180]. We therefore 
examined the activation of PARP enzyme following BC12 treatment. PARP cleavage 
was observed after 6 hours post treatment by Western blotting (Figure 32). Taken 
together, these data confirm that LY18 cells undergo apoptosis through activation of 
caspase 8 and caspase 3, following BC12 treatment.  
 We then sought to test BC12 derivatives on LY18 cell viability. Among the six 
compounds tested, BC12-7 and BC12-4 showed strong effects in inducing cell death. 
BC12-1, BC12-2 and BC12-6 had minimal effects on LY18 viability (Figure 33B). 
Comparing the structures of BC12, BC12-7 and BC12-4, we can speculate that 
substitutions of R3 and R1 are well tolerated in eliciting the effects. In contrast, 
substitution of R2 affects in vivo activity (Figure 33A). To note that BC12-6 is the best 
PDE7A inhibitor based on in vitro kinase assay among the seven derivatives and BC12-4 
does not have any PDE inhibitory activity (refer to Chapter One Figure 7). Thus, the 
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effectiveness in inducing cell death was not correlated to the PDE inhibitory activity of 
the compounds, which suggests that the effect of inducing apoptosis in LY18 cells is 
probably not attributable to PDE inhibition. 
 Next, we sought to examine cell cycle progression in LY18 cells treated with 
BC12. The overlay graphs represent total cell counts (Figure 34A), while the bar graphs 
represent the percentage of cells in each phase of cell cycle (Figure 34B and C). At 24 
hours post treatment, 10 µM of BC12 did not significantly alter cell cycle progression, 
except for a small decrease in S+G2/M-phase and increase in sub-G0/G1-phase, which 
indicates apoptotic cells (Figure 34A, 34B and 34C, 24hrs). At 48 hours, 10 µM of BC12 
decreased the G0/G1 cell population from 70% to 48% compared to untreated cells 
(Figure 34A and 34B, 48hrs). Treating with 20 µM of BC12 decreased the G0/G1 cell 
population from 57% to 44% at 24 hours and from 70% to 41% at 48 hours, resulting in 
an increase in sub-G0/G1 population (Figure 34A and 34B). Notably, BC12 did not 
measurably affect both cell counts and percentage of S+G2/M-phase population at both 
time-points (Figure 34A and 34C). These data indicate that BC12 does not cause cell 
cycle arrest in LY18 cells and preferably induces apoptosis in cells in G0/G1-phase. 
 Finally, we tested BC12 on human primary B cell viability. Human primary B 
cells were obtained from healthy donors' blood and treated with increasing dose of BC12 
for 24 and 48 hours. BC12 induced about 70% cell death at doses of 50 µM or higher. At 
a dose of 20 µM, BC12 induced about 50% cell death in human primary B cells (Figure 
35), as compared to about 95% cell death in LY18 cells (Figure 29). Taken together, 
BC12 induces cell death in human primary B cells in a dose-dependent manner, while 
prolonged treatment did not significantly increase the effectiveness. Moreover, there 
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exists a dose window that BC12 induces significantly higher percentage of cell death in 
human malignant LY18 cells than primary B cells. 
 
BC12 induces apoptosis in U937 cells 
 U937 is a human leukemia monocyte cell line [166]. We sought to use the U937 
cell line as a model system for human malignant monocytes. To investigate the effects of 
in vitro PDE inhibitors on U937 cells, we started with testing four compounds on U937 
cells at a dose of 20 µM for 24 and 48 hours (Figure 36).  Similarly as in LY18 cells, 
BC12 treatment resulted in above 90% cell death at both time-points. BC38 induced 
approximately 33% cell death at 48 hours, while both BC51 and BC54 did not exhibit 
measurable effects on U937 cell viability compared to media control (Figure 36). A dose-
dependent effect of BC12 was confirmed by titration of BC12 on U937 cell viability for 
24 and 48 hours (Figure 37). BC12 potently decreases U937 cell viability at a dose of 20 
µM, but not 10 µM (Figure 37). 
 Next, we sought to determine whether U937 cells were undergoing apoptosis after 
BC12 treatment by TUNEL assay (Figure 38). At both 24 and 48 hours, 10 µM of BC12 
only showed a minimal effect in inducing apoptosis compared to DMSO control. 
Treating cells with 20 µM of BC12 induced about 80% apoptosis at 24 hours and 70% at 
48 hours (Figure 38). These results confirmed that decreased U937 cell viability by BC12 
treatment was due to apoptosis. 
 We then evaluated caspase and PARP activation in U937 cells. Similarly as in 
LY18 cells, caspase 8 and caspase 3 were both cleaved and activated in U937 cells 
treated with 20 µM of BC12 (Figure 39A and 39B). The full-length caspase 8 and 3 
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started to decrease at 9 hours to about 50% and 20% respectively. Cleavage of both 
caspase 8 and 3 was observed beginning at 6 hours, which continued to increase from 6 
hours to 12 hours post treatment. Both full-length and cleaved caspase 8 were almost 
undetectable at 24 hours (Figure 39A, BC12). PARP cleavage was observed at 6 hours 
and almost completed at 12 hours (Figure 40). Staining and flow cytometric analysis 
indicated that about 90% of cells activated caspase 3 at 12 to 48 hours (Figure 39B). 
Interestingly, unlike LY18 cells, in which a great amount of caspase proteins remained in 
pro-enzyme forms, majority of the caspase 8 and 3 proteins were cleaved and activated 
during the apoptosis process in U937 cells (Figure 39 and 31).  
 Next, we also evaluated cell cycle progression of U937 cells treated with BC12. 
Treating with 10 µM of BC12 decreased the percentage of cells in G0/G1 phase by 
approximately 15% at all time points examined and S+G2/M phase by 10% at 15 and 24 
hours, resulting in increased hypodiploid DNA (Figure 41A, 41B and 41C). 20 µM of 
BC12 resulted in a 30-40% decrease in G0/G1 phase, a 10-20% decrease in S+G2/M 
phases, and an increase in hypodiploid DNA (Figure 41A, 41B and 41C).  These data 
indicated that BC12 did not halt cell cycle progression of U937 cells. 
 To obtain further evidence that BC12 does not block cell cycle progression in 
U937 cells, we sought to examine the level of DNA synthesis by BrdU incorporation 
(Figure 42). 40% of DMSO treated control cells incorporated BrdU at 24 hours and 35% 
at 48 hours (Figure 42, DMSO). Compared to media or DMSO control, BC12 treatment 
resulted in a slight increase in the percentage of cells with BrdU incorporation, 
approximately 57% at both 24 and 48 hours (Figure 42, BC12). This increase in 
percentage is very likely due to a higher amount of cell loss in other phases of cell cycle 
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than in S-phase, since the cells were undergoing apoptosis after BC12 treatment. Taken 
together, these results suggest that BC12 did not block cell cycle progression or inhibit 
DNA synthesis in U937 cells. 	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FIGURES AND LEGENDS 
Figure 28. In vitro PDE7 inhibitors have various effects on LY18 cell viability. A, 
LY18 cells were cultured in media in the presence of DMSO, or various in vitro PDE 
inhibitors with increasing doses (0.1 µM, 1 µM, 10 µM, 50 µM and 100 µM) for 48 
hours. Titration of BC54 was repeated at doses 10 µM, 50 µM and 100 µM. Treatment 
with other compounds was repeated at the highest dose. B, LY18 cells were cultured in 
media, or in the presence of 20 µM in vitro PDE inhibitor BC12, BC38 or rolipram for 
indicated lengths of time. Cells were collected and cell viability was determined by 
propidium iodide staining. Samples were analyzed by flow cytometry as described in 
Material and Methods. The data are represented as the percentage of cells that are 
positive for propidium iodide staining. The data are representative of 10,000 cells.  
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Figure 28 
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Figure 29. BC12 induces dose-dependent decrease of cell viability in LY18 cells. 
LY18 cells were cultured in media alone, or with increasing dose of BC12 (0.1 µM, 1 
µM, 10 µM, 20 µM and 50 µM). At the indicated times, cells were collected and cell 
viability was determined by propidium iodide staining. Samples were analyzed by flow 
cytometry as described in Material and Methods. The data are represented as the 
percentage of cells that are positive for propidium iodide staining. The data are 
representative of 10,000 cells. Titration of BC12 was repeated at doses 10 µM, 20 µM 
and 50 µM. The same trend was observed in two independent experiments. 
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Figure 29 
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Figure 30. BC12 induces apoptosis in LY18 cells. LY18 cells were cultured in media 
with DMSO, 10 µM or 20 µM of BC12. At the indicated times, cells were collected and 
cell apoptosis was analyzed by TUNEL assay as described in Material and Methods. The 
data are represented as the percentage of cells that are positive for FITC staining. The 
data are representative of 10,000 cells, completed as two independent experiments. 
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Figure 30 
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Figure 31. BC12 activates caspase pathway in LY18 cells.	  A, LY18 cells were cultured 
in media with DMSO or 20 µM of BC12 for indicated lengths of time. Whole cell 
extracts were prepared and Western blotting was performed with anti-caspase 8 and anti-
caspase 3 antibodies that recognize both full length and cleaved caspases as described in 
Material and Methods. The blot was stripped and reprobed for anti-HSP90 antibody to 
ensure equal loading of each sample. Quantification of the Western blotting bands was 
obtained with ImageJ software (v1.45s). Both top and bottom band densities are listed as 
fold increase above first detected band relative to HSP90 loading control. The data are 
representative of two independent experiments. B, LY18 cells were cultured in media 
with DMSO or 20 µM of BC12 for indicated lengths of time. Cells were collected and 
stained with FITC-conjugated anti-active caspase 3 antibody, followed by flow 
cytometric analysis as described in Material and Methods. The data are represented as the 
percentage of cells that are positive for active caspase 3 staining. The data are 
representative of 10,000 cells, completed as two independent experiments. 
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Figure 31 
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Figure 32. BC12 induces PARP cleavage and activation in LY18 cells. LY18 cells 
were cultured in media with DMSO or 20 µM of BC12 for indicated lengths of time. 
Whole cell extracts were prepared and Western blotting was performed with anti-PARP 
antibody that recognizes full length and cleaved PARP as described in Material and 
Methods. The blot was stripped and reprobed for anti-HSP90 antibody to ensure equal 
loading of each sample. Quantification of the Western blotting bands was obtained with 
ImageJ software (v1.45s). Both top and bottom band densities are listed as fold increase 
above first detected band relative to HSP90 loading control. The data are representative 
of two independent experiments. 
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Figure 32 
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Figure 33. BC12 analogs have various effects on LY18 cell viability.	  LY18 cells were 
cultured in media, or treated with 20 µM of BC12 derivatives. Cells were collected at the 
indicated times and cell viability was determined by propidium iodide staining. Samples 
were analyzed by flow cytometry as described in Material and Methods. The data are 
represented as the percentage of cells that are positive for propidium iodide staining. The 
data are representative of 10,000 cells, completed as two independent experiments. 
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Figure 33 
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Figure 34. BC12 does not inhibit cell cycle progression in LY18 cells.	  LY18 cells 
were cultured in media alone or in the presence of 10 µM, or 20 µM BC12. At the 
indicated times, LY18 cells were stained with propidium iodide and cell cycle analyzed 
by flow cytometry as described in Materials and Methods. A, The data are presented as 
overlay graphs with the number of cells (counts) versus propidium iodide (PI-A). B, The 
data are represented as the percentage of LY18 cells in the G0/G1-phase of the cell cycle. 
C, The data are represented as the percentage of LY18 cells in the S+G2/M-phase of the 
cell cycle. The data are representative of 10,000 cells.  
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Figure 34 
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Figure 35. BC12 induces cell death in human primary B cells. Human primary B cells 
were isolated from donor's blood as described in Material and Methods. Cells were 
cultured in media alone, or with increasing dose of BC12 (0.05 µM, 0.5 µM, 2.5 µM, 5 
µM, 10 µM, 25 µM, 50 µM and 100 µM). At the indicated times, cells were collected and 
cell viability was determined by propidium iodide staining. Samples were analyzed by 
flow cytometry as described in Material and Methods. The data are represented as the 
percentage of cells that are positive for propidium iodide staining. The data are 
representative of 10,000 cells. Titration of BC12 was repeated at doses 10 µM, 25 µM, 
50 µM and 100 µM. The same trend was observed in two independent experiments. 
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Figure 36. In vitro PDE7 inhibitors have various effects on U937 cell viability. U937 
cells were cultured in media, or treated with various in vitro PDE7 inhibitors at a dose of 
20 µM. Cells were collected at the indicated times and cell viability was determined by 
propidium iodide staining. Samples were analyzed by flow cytometry as described in 
Material and Methods. The data are represented as the percentage of cells that are 
positive for propidium iodide staining. The data are representative of 10,000 cells.  
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Figure 36 
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Figure 37. BC12 induces dose-dependent decrease of cell viability in U937 cells. 
U937 cells were cultured in media alone, or with increasing dose of BC12 (0.5 µM, 1 
µM, 5 µM, 10 µM, 20 µM and 50 µM). At the indicated times, cells were collected and 
cell viability was determined by propidium iodide staining. Samples were analyzed by 
flow cytometry as described in Material and Methods. The data are represented as the 
percentage of cells that are positive for propidium iodide staining. The data are 
representative of 10,000 cells. Titration of BC12 was repeated at doses 10 µM, 20 µM 
and 50 µM. The same trend was observed in two independent experiments. 
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Figure 37 
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Figure 38. BC12 induces apoptosis in U937 cells. U937 cells were cultured in media 
with DMSO, 10 µM or 20 µM of BC12. At the indicated times, cells were collected and 
cell apoptosis was analyzed by TUNEL assay as described in Material and Methods. The 
data are represented as the percentage of cells that are positive for FITC staining. The 
data are representative of 10,000 cells and two independent experiments. 
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Figure 38 
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Figure 39. BC12 activates caspase pathway in U937 cells. A, U937 cells were cultured 
in media with DMSO or 20 µM of BC12 for indicated length of time. Whole cell extracts 
were prepared and Western blotting was performed with anti-caspase 8 and anti-caspase 
3 antibodies that recognize both full length and cleaved caspases as described in Material 
and Methods. The blot was stripped and reprobed for anti-HSP90 antibody to ensure 
equal loading of each sample. Quantification of the Western blotting bands was obtained 
with ImageJ software (v1.45s). Both top and bottom band densities are listed as fold 
increase above first detected band relative to HSP90 loading control. The data are 
representative of two independent experiments. B, U937 cells were cultured in media 
with DMSO or 20 µM of BC12 for indicated length of time. Cells were collected and 
stained with FITC-conjugated anti-active caspase 3 antibody, followed by flow 
cytometric analysis as described in Material and Methods. The data are represented as the 
percentage of cells that are positive for active caspase 3 staining. The data are 
representative of 10,000 cells, completed as two independent experiments. 
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Figure 40. BC12 induces PARP cleavage and activation in U937 cells. U937 cells 
were cultured in media with DMSO or 20 µM of BC12 for indicated length of time. 
Whole cell extracts were prepared and Western blotting was performed with anti-PARP 
antibody that recognizes full length and cleaved PARP as described in Material and 
Methods. The blot was stripped and reprobed for anti-HSP90 antibody to ensure equal 
loading of each sample. Quantification of the Western blotting bands was obtained with 
ImageJ software (v1.45s). Both top and bottom band densities are listed as fold increase 
above first detected band relative to HSP90 loading control. The data are representative 
of two independent experiments. 
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Figure 40 
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Figure 41. BC12 does not inhibit cell cycle progression in U937 cells.	  U937 cells were 
cultured in media alone or in the presence of 10 µM, or 20 µM BC12. At the indicated 
times, U937 cells were stained with propidium iodide and cell cycle analyzed by flow 
cytometry as described in Materials and Methods. A, The data are represented as the 
percentage of U937 cells in the G0/G1-phase of the cell cycle. B, The data are represented 
as the percentage of cells in the S+G2/M-phase. C, The data are represented as the 
percentage of cells in the sub-G0/G1-phase. The data are representative of 10,000 cells.  
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Figure 41 
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Figure 42. BC12 does not inhibit DNA synthesis in U937 cells. U937 cells were 
cultured in media alone, with DMSO or 20 µM of BC12. At the indicated times, cells 
were collected and DNA synthesis was monitored by BrdU incorporation and analyzed 
by flow cytometry as described in Materials and Methods. The data are representative of 
10,000 cells and are presented as cell number (counts) versus BrdU (FITC-A). The bars 
reflect the percentage of BrdU positive U937 cells. The data are representative of two 
independent experiments. 
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Figure 42 
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DISCUSSION 
 
I. Chapter One 
 PDE4 inhibitors have been proved effective therapeutic agents for alleviating 
chronic inflammation such as asthma and COPD. However, these inhibitors are 
compromised by dose-limiting side effects that are difficult to overcome [181]. PDE7A is 
proposed to be a new therapeutic target in addition to PDE4 [11], for its ubiquitous 
expression in proinflammatory and immune cells [22]. Emerging evidence has suggested 
that PDE7A plays an important role in regulating T cell activation [4, 5]. Despite the 
immunomodulatory potential of PDE7, selective inhibitors of PDE7 are lacking. 
BRL50481 is the only commercially available PDE7 inhibitor [27]. Herein, we 
characterized a novel in vitro PDE7 inhibitor, BC12, for its immunosuppressive activity 
in mammalian T cells.  
 IL-2 is a key cytokine of T cell activation. The de novo synthesis of IL-2 is an 
immediate event following TCR and costimulatory molecule ligation [57]. Using human 
Jurkat cells as a model for human T lymphocytes, we first demonstrate that BC12 inhibits 
IL-2 secretion in activated Jurkat cells in a dose-dependent manner without significantly 
reducing cell viability. Since IL-2 production is an outcome of gene expression, protein 
translation, transport and secretion, we were able to assesse the endogenous IL-2 protein 
level with the aid of a Golgi inhibitor and confirmed that BC12 inhibits endogenous IL-2 
protein production. Relative IL-2 mRNA levels were then evaluated by semi-quantitative 
real-time PCR. Our data demonstrate that IL-2 mRNA expression was blocked by BC12. 
We did not directly examine IL-2 protein translation; therefore cannot rule out the 
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possibility that IL-2 protein translation is also inhibited by BC12. It is important to note 
that the inhibitory effects of BC12 on both protein production and mRNA expression 
were initiated at the earliest time point we examined and persisted for at least 24 hours as 
the longest time point we observed.  
 As a key growth cytokine for T cells, IL-2 expression is controlled at multiple 
levels, including transcriptional and post-transcriptional regulation. IL-2 mRNA contains 
several AU-rich elements in 3'-UTR as well as additional elements in 5'-UTR and within 
the coding region, providing regulatory sites for mRNA stability in response to TCR and 
CD28 costimulation [123–127]. Our studies used CsA to inhibit IL-2 transcription by 
blocking calcineurin-dependent nuclear import of NFAT [146]. In the presence of CsA, 
we were able to assess IL-2 mRNA degradation rate by real-time PCR. Our results 
indicate that BC12 does not accelerate IL-2 mRNA degradation. Thus, inhibited IL-2 
gene expression by BC12 is due to transcriptional repression.  
 Transcriptional regulation of IL-2 gene is well characterized. Positive regulatory 
elements in the 300 bp minimal promoter region of IL-2 gene need to be occupied by 
corresponding transcription factors for optimal transcription [74]. Microarray analysis of 
the whole genome expression profile of Jurkat cells was performed to study the 
interaction effect of BC12 and stimuli. Among transcription factor families NFAT, 
NFκB, Fos, Jun and Oct-1, NFκB regulated genes are most affected by BC12. In NFκB 
family proteins, RelA (p65), NFκB1 (p50), and c-Rel are three demonstrated targets of 
TCR and CD28 signaling [88]. Western blotting of nuclear extracts suggests that all three 
proteins show impaired nuclear translocation in the presence of BC12. Inhibition of 
NFκB pathway was further validated by EMSA, indicating BC12 inhibits NFκB proteins 
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binding to their specific DNA probe. In resting T cells, NFκB heterodimers reside in 
cytoplasm in complex with IκB protein. Upon TCR/CD28 stimulation, nuclear 
translocation of NFκB depends on phosphorylation-induced degradation of IκB [86]. The 
multi-subunit IKK complex is the central component of the NFκB signaling pathway, 
which phosphorylates IκB and targets its ubiquitination [88]. Our data suggest that BC12 
suppresses NFκB pathway by inhibiting IκB phosphorylation and degradation. However, 
phosphorylation status of IKKα/β complex seems unaffected by BC12 based on Western 
blotting. The phospho-IKKα/β antibody in our study detects phosphorylation of 
Ser176/180 in IKKα and Ser177/181 in IKKβ, which is required for activation of IKK 
complex [183–185]. To directly assess the kinase activity of the IKK complex, 
IKKα/β kinases can be immunoprecipitated from cells treated with stimuli and BC12. In 
vitro kinase assay can be conducted using recombinant IκB protein as a substrate. In 
addition to IKKα/β phosphorylation, recent findings have demonstrated other regulatory 
mechanisms required for IKK activation [20, 21]. Specifically, in complex with the 
catalytic subunits IKKα/β, IKKγ is an essential structural and regulatory subunit of the 
IKK complex [20, 22] and IKK activation depends on IKKγ polyubiquitination [20, 21]. 
A recent publication reports that a compound cordycepin suppresses NFκB activation by 
blocking IKKγ ubiquitination [188]. Therefore, we can also evaluate other modifications 
of IKK complex in addition to IKKα/β phosphorylation. 
 In addition to NFκB, our EMSA data also suggest that the NFAT pathway is 
inhibited by BC12 in activated Jurkat cells. Two different NFAT binding DNA probes 
were used to validate the findings. Super-shift assay using anti-NFATc2 and anti-
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NFATc1 antibodies reveals that both NFAT family proteins are present in the nucleus to 
bind to the DNA probe. However, Western blotting of nuclear proteins indicated that 
nuclear translocation of NFATc2 protein was not significantly affected. Since the 
preparation of nuclear extracts may result in inter-contamination of nuclear and 
cytoplasmic proteins, other approaches can be employed to validate the data. 
Immunofluorescence microscopy using antibodies specific to NFATc2, NFATc1, and 
other transcription factors of interest can be used to image the localization of the proteins 
in response to stimuli and BC12.  
 As our studies demonstrate thus far, BC12 inhibits IL-2 gene transcription in 
activated Jurkat cells through NFκB and NFAT-mediated pathways. To validate our 
findings based on EMSA, we attempted chromatin immunoprecipitation (ChIP) using 
antibodies specific to NFATc2 or RelA(p65) and amplified precipitated DNA using 
primers specific to IL-2 promoter region. However, the ChIP experiments were not 
successful due to low affinity of the antibodies. This approach could be repeated if 
antibodies with high affinity are available. Furthermore, luciferase assay with NFAT or 
NFκB-driven reporter gene transfected to Jurkat cells can be used to confirm the 
inhibitory effect of BC12 on these pathways.  
 Importantly, although we initially hypothesized PDE7 as the in vivo target of 
BC12 in Jurkat cells, we found that BC12 inhibited IL-2 transcription not through PDE 
by comparison analysis. BC12-4, BC12-6, BC54 and BC12 were used to treat Jurkat cells 
simultaneously with stimuli. Besides BC12, its structural analog BC12-4 displayed potent 
inhibitory effects on IL-2 production in activated Jurkat cells. The extent of reduction in 
IL-2 production by BC12-6 and BC54 was approximately 25%, similar to that of 
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commercially available PDE4 inhibitor rolipram (unpublished data by Hoffman Lab). 
Among these compounds, BC54 is the most potent PDE4 and PDE7 dual inhibitor; 
BC12-6 and BC12 exhibit similar PDE7A inhibitory activity in in vitro PDE assay; 
BC12-4 has no measurable PDE7A inhibitory activity (unpublished data by Hoffman 
Lab).  Thus, we can speculate that the inhibitory effect on IL-2 production is not 
correlated with their in vitro PDE inhibitory capacity. However, the possibility that BC54 
and BC12-6 have a lower accessibility to cells although treated at the same dosage, 
cannot be completely ruled out. This issue was partially addressed by previous studies 
from Hoffman Lab, which showed that BC54 potently inhibited TNFα secretion from 
U937 cells and induced apoptosis in B-CLL cells (unpublished data). These findings 
demonstrated an anti-inflammatory effect of BC54 and its ability to cross the cell 
membrane. To further confirm that PDE7 is not the in vivo target of BC12 that leads to 
IL-2 inhibition, intracellular cAMP levels can be assessed after cells were treated by 
BC12. Alternatively, cAMP antagonist that specifically inhibits downstream effector 
enzymes such as PKA can be used along with BC12 to treat Jurkat cells. If BC12 works 
through elevating intracellular cAMP level by inhibiting PDE, its effect should be 
reversed by a cAMP antagonist.  
 Structurally, BC12 is a barbiturate-based compound. Accumulating evidence 
suggests that clinical use of barbiturates for neuroprotection is associated with a loss of 
protective immunity as a side effect [24, 25]. It has been reported that barbiturates, such 
as thiopental and thiamylal, directly inhibit calmodulin/calcineurin complex, leading to 
inhibition of NFAT pathway. NFAT-driven reporter genes, as well as IL-2 and IFNγ 
production in activated human T lymphocytes, were suppressed [29]. Another report also 
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indicates that thiopental inhibits NFκB mediated transcription in Jurkat cells and human 
primary T lymphocytes, with possible involvement of reduced degradation of IκBα 
[191]. Thiopental has some level of structural similarity with BC12; however, the dose of 
thiopental reported to achieve an inhibitory effect on IL-2 production is more than 100-
fold higher than BC12 [29].  
 Inhibitors of T cell activation function through targeting different pathways. 
Cyclosporin A (CsA) and tarolimus target calcium calmodulin-dependent phosphatase 
calcineurin, thus inhibit NFAT regulated IL-2 expression [146]. Rapamycin blocks IL-2 
post-receptor signaling by targeting mTOR [144]. PDE4/7 dual inhibitors, such as T-
2585, inhibit human T cell proliferation and cytokine production [182]. Our compound 
BC12 inhibits T cell activation by targeting NFAT and NFκB pathways. It is important to 
note that BC12 does not completely block either pathway; instead, partially reduces the 
activity of both pathways, resulting in suppression of IL-2 expression. Recently, therapies 
that target multiple pathways have been increasingly designed to achieve a collective 
effect to treat complex diseases such as cancer [192]. It has been suggested that partial 
inhibition of multiple targets can be more efficient than the complete inhibition of a 
single target [193]. Therefore, BC12 can be a very promising multi-target drug that 
inhibits T cell activation. 
 An interesting finding from our study is that BC12 augments phosphorylation 
status of signaling proteins in the AP-1 signaling pathway in stimulated Jurkat cells, 
while BC12 alone does not induce activation of signaling pathway. In agreement with the 
Western blotting data, EMSA result suggests that BC12 considerably increases the 
binding of AP-1 proteins to their specific DNA probe. We also conducted ChIP 
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experiment using antibody specific to c-Jun (data not shown), which showed increased 
occupation of c-Jun to IL-2 promoter region when treated with BC12 along with stimuli. 
Microarray data also indicate that the expression levels of several AP-1 regulated genes 
are increased by BC12 in the presence of stimuli. Taken together, BC12 augments AP-1 
signaling pathway, resulting in increased binding of AP-1 to its corresponding regulatory 
elements in DNA, which may be responsible for increased expression of c-Fos, c-Jun and 
IL-8 as revealed by microarray data. However, the relation between increased AP-1 
activation and inhibited IL-2 expression has not been resolved. Feedback loops 
commonly exist to regulate signaling pathways. It has been reported that IL-2 
transcription is transient and self-limited by an auto-regulatory feedback loop, in which 
IL-2 inhibits its own expression [58]. We can speculate that a novel feedback loop may 
exist such that repressed downstream IL-2 expression resulted in hyper-activation of 
upstream signaling pathways. Further experiments need to be conducted to validate this 
hypothesis.  
 We further investigated the effects of BC12 and its derivative compounds in 
activated mouse and human primary T cells. Our findings in Jurkat cells were well 
recapitulated in both primary T cell cultures. Specifically, BC12 and BC12-4 both inhibit 
IL-2 production in activated mouse and human primary T cells, whereas BC12-6 does not 
exhibit a significant effect. It was confirmed in human primary T cells that inhibition of 
IL-2 production is attributable to transcriptional repression by real-time PCR. It is 
important to note that BC12 alone, or in combination of stimuli does not induce 
significant cell death at the dose that inhibits IL-2 production. Therefore, the 
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immunosuppressive activity of BC12 is not limited to transformed cell line, but also 
effective in primary T cells. 
 CD4+ helper T cells are divided into distinct subsets based on cytokine production 
and immune function. Th1 cells produce IL-12 and IFNγ, promoting cell-mediated 
immune response. Th2 cells produce IL-4, IL-5 and IL-13, promoting humoral immunity. 
Th17 cells produce IL-17, IL-22 and IL-6, which mediate neutrophil inflammation and 
are increasingly implicated in steroid-insensitive asthma [194]. We sought to investigate 
the effect of BC12 on T helper cell specific cytokine secretion in activated human 
primary CD4+ T cells. Our data indicate that BC12 selectively inhibits Th2 cytokine and 
some of the Th17 cytokine secretions. Production of the key Th1 cytokine IFNγ is not 
significantly affected by BC12. These findings, although preliminary, are very promising. 
Abnormal polarization of Th2 response is a key event in allergic diseases. Predominant 
Th2 profile cytokine expression and a reduced production of Th1 cytokine IFNγ is noted 
[141]. Th2 cytokines drive the differentiation and function of B cells and mast cells. IL-4 
promotes antibody class-switching in B cells, leading to the secretion of IgE. IgE binds to 
receptors on mast cells, resulting in release of mediators such as histamines that lead to 
tissue inflammation. IL-5 stimulates B cell growth and antibody secretion and mediates 
eosinophil activation [195]. Immunomodulatory compounds such as suplatast tosilate, 
which inhibits IL-4 and IL-5 production but not IFNγ [196], have been proven effective 
in clinical application [32, 33]. The potential of BC12 on selectively inhibiting Th2 
cytokines is a very interesting and promising direction for developing novel therapeutic 
agents to treat allergic diseases. Further experiments need to be carried out to confirm the 
effects of BC12 on key cytokine production and gene expression such as IL-4, IL-5 and 
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IFNγ. Instead of total CD4+ T cells, Th1 and Th2 cells can be induced for more specific 
analysis. Furthermore, in addition to cytokine inhibition, BC12 can be tested for its 
potential to inhibit Th2 cell differentiation and to increase Th1/Th2 ratio.  
 In summary, our studies report that BC12, a novel in vitro PDE7 inhibitor, 
inhibits IL-2 expression in activated Jurkat cells, mouse and human primary T cells, by 
targeting NFAT and NFκB-mediated pathways as summarized in Figure 7. Moreover, 
our findings also suggest that BC12 has a potential to selectively inhibit Th2 cytokines. 
The immunosuppressive and potential immunomodulatory effects mark BC12 a 
promising therapeutic agent that worth further investigation.  
 
Figure 7. Summary of mechanism of inhibition of BC12.  
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II. Chapter Two 
 Elevating intracellular cAMP levels can result in growth arrest and apoptosis in 
cancer cells, marking PDEs as potential targets for cancer treatment [199]. The 
development of family-specific PDE inhibitors allows insight into the therapeutic effects 
of targeting specific PDEs. PDE inhibitors have been shown to induce apoptosis in 
hematological malignant cells, either alone or in synergy with glucocorticoids [6–10]. It 
was reported that PDE4B overexpression correlates with higher risk of relapse of DLBCL 
and limits cAMP-associated apoptosis in DLBCL [10]. PDE7B overexpression was 
observed in B-CLL [7]. Both inhibitors of PDE7 and a dual inhibitor of PDE4/7 
selectively induce apoptosis in CLL cells compared to normal B cells, suggesting PDE7B 
as a potential therapeutic target for CLL [7]. However, inhibitors that selectively and 
potently inhibit PDE7B are in need to confirm its role in CLL malignancy. As the only 
commercially available PDE7 specific inhibitor, BRL50481 is a potent PDE7A inhibitor 
with IC50 of 150 nM, but poor PDE7B inhibitor with IC50 of 12 µM [28]. Our novel in 
vitro PDE7 inhibitor BC12 inhibits PDE7A catalytic domain with IC50 of 1 µM and full-
length rat PDE7B with IC50 of 200 nM, exhibiting significantly stronger PDE7B 
inhibitory activity than BRL50481. 
 Using human LY18 cell line and U937 cell line as models for human DLBCL 
cells and malignant monocytes, we characterized the ability of several PDE4 and/or 
PDE7 inhibitors to induce cell death in human malignant B cells and monocytes. Our 
data demonstrate that BC12 is the most potent compound among several in vitro PDE 
inhibitors to induce cell death in both cell lines. BC12 induces cell death in a dose-
dependent manner. With a dose of 20 µM, BC12 results in approximately 90% cell death. 
	  	   168	  
To compare the effect of BC12 on normal B cells and malignant LY18 cells, we also 
titrated BC12 on human primary B cell viability. At 20 µM, BC12 induces significantly 
less cell death in primary B cells than in LY18 cells, suggesting that BC12 has selectivity 
in killing DLBCL cells over normal B cells. Of note, cell lines usually derive from high-
grade malignancies that carry greater abnormalities than primary tumor samples for its 
ability to survive in cell culture environment. Therefore, BC12 has the potential to be 
more effective in killing primary DLBCL cells than LY18 cell line.  
 We also confirm that BC12 induces apoptosis in both LY18 and U937 cells, 
evidenced by DNA fragmentation and caspase pathway activation, which results in the 
decreased viability. There are two main pathways of apoptosis in vertebrates, the 
extrinsic and intrinsic pathways [200]. Extrinsic signals ligate death receptors such as Fas 
receptor to activate initiator caspases such as caspase 8. Initiator caspases cleave and 
activate effector caspases, such as caspase 3 and caspase 7. In the intrinsic pathway, a 
BH3-only protein such as Bid triggers mitochondria permeabilization and cytochrome c 
release to cytosol. Cytochrome c triggers the oligomerization of Apaf-1 and formation of 
the apoptosome, where caspase 9 is activated. Caspase 9 cleaves and activates effector 
caspases such as caspase 3 and caspase 7 [200]. Our data revealed that caspase 8 and 
caspase 3 are activated in both cell lines treated with BC12, suggesting an involvement of 
extrinsic pathway in BC12 induced apoptosis. The contribution of intrinsic pathway 
cannot be ruled out and needs to be further investigated. Inhibition of cell cycle 
progression can ultimately lead to apoptosis. Cell cycle analysis and BrdU staining 
revealed that BC12 does not cause cell cycle arrest; instead, directly induces apoptosis 
while cells are still proliferating. 
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 To decipher the correlation of in vitro PDE7 inhibitory activity and apoptotic 
effects in LY18 cells, derivative compounds of BC12 were tested on LY18 cell viability 
for structural-activity analysis. BC12-4, which has no PDE7 inhibitory activity, reduces 
LY18 cell viability to the similar level as BC12. In contrast, BC12-6, which is the most 
potent PDE7 inhibitor among the derivatives except BC12, does not decrease LY18 
viability. In addition, BC54, the most potent PDE4/7 dual inhibitor, does not exhibit any 
effect on LY18 viability up to a dose of 100 µM. These data all together suggest that the 
in vivo target of BC12 that induces apoptotic effects in LY18 cells is not PDE7. It is 
important to note that the apoptotic effects of BC12 derivative compounds in LY18 cells 
coincide with the IL-2 inhibitory effects in Jurkat cells as investigated in Chapter One. 
Specifically, BC12, BC12-7, BC12-4 and BC12-5 all displayed potent effects in both cell 
lines, whereas BC12-1, BC12-2 and BC12-6 did not. Based on these findings, we can 
speculate that the in vivo targets that lead to either IL-2 inhibition in Jurkat cells or 
apoptosis in LY18 cells may be the same.  
 In Chapter One, we demonstrate that NFκB pathway is inhibited by BC12 in 
human Jurkat cells. NFκB factors regulate a vast series of genes in immune cells that 
control inflammation, cell growth, differentiation or apoptosis [201]. Aberrant activation 
of NFκB pathway has been frequently observed in hematologic malignancies and NFκB-
blocking approaches have been investigated as anti-caner strategies [201]. A compound 
specifically targeting NFκB activity by inhibiting IκB phosphorylation induces apoptosis 
of CLL cells in a dose-dependent manner [202]. The pro-apoptotic effect of NFκB 
inhibitor rely on the block of NFκB-mediated expression of apoptosis-modulating genes, 
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such as BCL-2 family genes [201]. Moreover, NFκB and tumor suppressor p53 can 
inhibit each other's transactivation possibly through competing for binding to the 
p300/CBP coactivator [203]. It is important to note that LY18 cells carry rearranged p53, 
BCL-2 and MYC genes [160]. MYC promotes cell growth activity, whereas p53 and 
BCL-2 mutation permit the cells to escape apoptotic death and are responsible for the 
resistance of the cell line to anti-cancer treatment [160]. Taken together, we can 
hypothesize that inhibiting p53 and BCL-2 activity by targeting NFκB pathway can 
induce a differential apoptotic effect between LY18 cells and human normal B cells, 
which is a reasonable mechanism of action by BC12. Further experiments need to be 
conducted to confirm this hypothesis.  
 In summary, our data demonstrate that BC12 induces apoptosis in human LY18 
and U937 cell lines in a dose-dependent manner. Titration of BC12 on LY18 cells and 
human primary B cells revealed that BC12 induces cell death more effectively in DLBCL 
LY18 cell line than normal B cells, which merits this compound further investigation as 
an anti-cancer agent. 
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